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Abstract
A normally developed placenta is integral to a successful pregnancy. Preeclampsia (PE)
and intrauterine growth restriction (IUGR) are two common pregnancy related
complications that result from abnormal placental development. Placental microRNAs
(miRNAs) have been investigated as potential biomarkers for these complications, but
they may also play a role in placental development and pathophysiology by influencing
gene expression. The objectives of this study are (i) to utilize next-generation sequencing
to determine miRNA and gene expression in human placental (chorionic villous) samples
from three distinct patient groups with early-onset (EO) PE, IUGR, or PE + IUGR, and
(ii) integration of expression datasets to assess the impact of dysregulated miRNAs on
gene expression and trophoblast cell function. Placental tissues were collected from four
patient groups (control [N=21], EO-PE [N=20], EO-IUGR [N=18], and EO-PE + IUGR
[N=20]), and total RNA was used for miRNA and RNA sequencing. Multiple differential
expression analysis programs were used to analyze both expression datasets in each
patient group compared to gestational age-matched controls. Inverse correlation analysis
and target prediction software were used to identify gene targets. Candidate gene targets
identified were confirmed using luciferase assays, and impact of miRNAs on trophoblast
function was assessed using proliferation and migration assays in HTR-8/SVneo cells.
Analysis revealed miRNAs and genes that are disease-specific, as well as others that are
common between disease groups, 6 microRNAs and 22 genes were identified to be
differentially expressed in all three patient groups. In addition, integrative analysis
between the miRNA and gene expression datasets revealed candidate gene targets for
miR-193b-5p and miR-210-5p, two miRNAs that also have an impact on trophoblast cell
i

functions. Our findings suggest common underlying placental pathologies in EO-PE and
EO-IUGR. Dysregulated miRNAs and genes identified in this study provide further
evidence for trophoblast dysfunction in these pregnancy complications. Integration of
miRNA and RNA profiling in the same three subgroups of pregnancy complications,
provides an alternate level of molecular information and is a useful tool to expand our
understanding of molecular perturbations in the placenta in early onset diseases.
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Chapter 1

1

Introduction

1.1 The Placenta
1.1.1

Placental Development

Placental development in humans begins shortly after the successful implantation of the
blastocyst which occurs 6-7 days post-conception (PC).1 The blastocyst at this time is
composed of the outer trophoblast layer known as the trophectoderm which will form the
placenta, and the inner cell mass (ICM) which will form the embryo.1,2 Following
successful blastocyst implantation, the outer trophoblast cell layer undergoes rapid
proliferation to form two layers of trophoblast cells, the inner cytotrophoblast (CT) layer
and the outer syncytiotrophoblast (SCT) layer.1-3 The SCT cell layer is formed as a result
of the fusion of CT cells and the CT layer becomes the main regenerative cell layer.1,2 By
day 8 PC the syncytiotrophoblastic mass expands over the entire surface of the
blastocyst.1
During days 8-13 PC spaces within the syncytiotrophoblastic cell mass known as lacunae
begin to form and expand.1,2 Also during this time, CT cells begin to differentiate into
either the villous trophoblast (VT) or the extravillous trophoblast (EVT) pathway.1-4 The
villous CT cells fuse to form the SCT layer, which grows to form pillars of SCT cells
separated by the lacunae known as trabeculae.1,2 The extravillous CT cells evaginate the
SCT layer building cell columns at the terminal ends that differentiate further into
endovascular or interstitial trophoblast.1-4 Extravillous CT cells invade as much as one
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third of the maternal myometrium, this process of trophoblast invasion is important for
establishment of maternal blood flow into the utero-placental unit, however blood flow at
this time is limited due to “plugging” of maternal arteries by the endovascular CT cells.1,2
In the EVT pathway, interstitial CT cells further differentiate into placental bed giant
cells that promote expansion of the placental site.1-4 The evagination of the SCT layer by
extravillous CT cells marks the early development of chorionic villous structures in the
placenta.1-4
Chorionic villous development continues with proliferation and fusion of CT cells to
expand the SCT layer.1,2,4 The distal ends of the trabeculae fuse together forming the
trophoblastic shell, and the trabeculae become the basis for primitive villous trees,
meanwhile the lacunar system begins to transform into the intervillous space.1 Fetal
mesenchymal cells migrate and grow into primary villi transforming them into secondary
villi.1,2,4 Finally, by day 18-21 PC fetal vascularization of the villi commences, as
secondary villi further expand into tertiary villi.1,2,4
Maternal spiral arteries are “unplugged” at 10-12 weeks of pregnancy and maternal blood
flows into the intervillous space increasing oxygen tension from 20 mmHg to 60
mmHg.1,2,4 The increase in oxygen tension triggers remodeling of maternal spiral arteries
by endovascular CT cells, this is important to dilate arteries in order to accommodate for
increased blood flow to the feto-placental unit, and to relinquish maternal vasomotor
control of spiral arteries.1-4 The maternal and fetal circulations come into close contact
with each other but are separated by 4 main layers, (1) continuous SCT layer that lines
the intervillous space; (2) layer of CT cells (attenuates in 2nd and 3rd trimester); (3)
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trophoblastic basal lamina; and (4) fetal endothelium.1,2 Figure 1.1 shows a sagittal
section of the mature placenta, as well as a chorionic villus tree, and a cross section of the
chorionic villus branch.

1.1.2

Placental Function

During gestation, the placenta along with fetal membranes and the amniotic fluid work
together to maintain normal growth and development of the fetus. The placenta has three
main important functions: (1) it is the main site of nutrient, oxygen and waste exchange,
(2) it also functions as an endocrine tissue that regulates the intrauterine milieu through
production and regulation of hormone levels, and (3) it protects the fetus against infection
and xenobiotic molecules.2,5
In the mature placenta, the fetal aspect is called the chorionic plate, and the maternal
aspect is called the basal plate (Figure 1.1a) .1,2 In between is the intervillous space
containing the main functional units of the placenta, the chorionic villi (Figure 1.1a).1,2,4
At the terminal regions of the chorionic villi is where maternal-fetal exchange occurs,
maternal blood containing necessary oxygen and nutrients (carbohydrates, amino acids,
lipids, vitamins, minerals) enters the intervillous space via the remodeled spiral arteries,
meanwhile oxygen-deficient blood and waste products drain through the endometrial
veins (Figure 1.1a).2,5 As an endocrine tissue, the placenta releases hormones into the
maternal and fetal circulation in order to regulate processes such as fetal growth,
metabolism, and parturition.2,5 The placenta produces endocrine, paracrine, and autocrine
factors. Examples of these factors include but are not limited to: estrogen, progesterone,
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placental growth hormone, and a number of growth factors such as insulin like growth
factors I and II.2,5 As a protective tissue the placenta is equipped with export pumps and
enzymes that can metabolize drugs and xenobiotic molecules.2,5

Figure 1.1 Sagittal and cross-sectional views of mature placental structure
A. Sagittal view of the mature placental after complete development in the 2nd trimester,
which includes the chorionic plate, the basal plate decidua, and B. the main functional
unit of the placenta- the chorionic villus tree within the intervillous space. C. Crosssection view of the terminal villi showing layers that separate maternal and fetal
circulation.
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1.1.3

Pregnancy Complications: PE

Preeclampsia (PE) is a maternal pregnancy complication that impacts 2-8% of
pregnancies.6,7 The two hallmarks of PE are (1) maternal systolic pressure greater than
140 mmHg and diastolic pressure greater than 90 mmHg, and (2) 24-hour proteinuria of
> 0.3 g; these are the current criteria used for diagnosis of PE.6,7 There are a number of
risk factors that could increase the likelihood of developing PE during pregnancy. Many
of those factors are maternal, including maternal diabetes, preexisting hypertension, and
obesity.6-8
One of the leading hypotheses on the pathogenesis of PE states that this maternal
systemic disturbance is due to poor remodeling of maternal spiral arteries by EVT cells
(Figure 1.2).6-9 Extravillous CT cells are responsible for migration, invasion and
remodeling of maternal spiral arteries to accommodate for increased blood flow into the
feto-placental unit necessary for fetal development.6-9 If this highly coordinated, complex
process doesn’t occur properly, it results in shallow and incomplete remodeling of spiral
arteries that remain partly under maternal vasomotor control and in poor placental
perfusion.8,9 Poor placental perfusion results in oxidative stress and chronic placental
ischemia, this triggers the release of antiangiogenic factors and proinflammatory
cytokines from the placenta into maternal circulation resulting in a systemic maternal
disturbance during pregnancy.8,9 Examples of antiangiogenic factors commonly identified
in preeclamptic maternal plasma include sFLT-1 and Endoglin.8,9 On the other hand, the
specific mechanisms by which extravillous CT cells fail to properly remodel maternal
spiral arteries are currently under investigation.
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The only cure for PE currently is the delivery of the fetus and the placenta, therefore both
maternal and fetal health are at risk, were chances of preterm birth are higher and adverse
effects on maternal health are imminent. Patients are currently classified into early- and
late- onset PE depending on onset and severity of symptoms.6,7 In early-onset patients
symptoms appear prior to 34 weeks of gestation and are more likely to be severe, and at
times associated with HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelet
count).6,7 In late-onset patients symptoms appear after 34 weeks of gestation and in many
cases patients deliver at term or late preterm with proper management of symptoms.6,7

1.1.4

Pregnancy Complications: IUGR

Intrauterine growth restriction (IUGR) is characterized by poor fetal growth in utero,
where estimated weight of the fetus is less than the 10th percentile for gestational age and
gender.10,11 Based on current diagnosis criteria for IUGR, it may occur early in pregnancy
(< 32 weeks) or later (> 32 weeks), defined as early- and late-onset of IUGR
respectively.12 It is now known that IUGR and small for gestational age (SGA) are
distinct. IUGR refers to pathological asymmetric fetal smallness that is commonly
associated with poor feto-placental Dopplers, whereas SGA refers to non-pathological
constitutional fetal smallness that is more commonly associated with normal fetoplacental Dopplers.10-12 IUGR is also associated with significant perinatal morbidity and
mortality, as well as adverse postnatal outcomes.10
There are maternal and fetal risk factors associated with the etiology of IUGR. Similar to
PE, maternal risk factors include diabetes, obesity, smoking and alcohol consumption.10,11
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Fetal risk factors include chromosomal and genetic abnormalities, congenital heart
defects, and infection.10,11 However, in many cases the etiology of IUGR can be
attributed to placental insufficiency, an encompassing condition in which the placenta
fails to function normally and the pathophysiology of which is not well understood.10-12
Diagnosing IUGR can be challenging, although biochemical testing in maternal plasma in
the first trimester can be used as an indicator of placenta related complications, the
sensitivity and specificity of the results are not sufficient for concrete diagnosis of
placental dysfunction.10,11 Feto-placental Doppler ultrasound is currently the most reliable
tool for diagnosing IUGR.12 More specifically, umbilical artery Doppler is used to assess
placental function during pregnancy, absent or reverse end diastolic flow (AEDF or
REDF) indicates severe placental impairment.10-12 Poor umbilical artery Dopplers
indicative of deteriorating placental function is a finding more commonly associated with
early-onset IUGR, and more often necessitates early delivery of the fetus to avoid
mortality in utero.10-12
Early-onset IUGR is also commonly associated with gestational hypertension and PE.12
The theory of impaired trophoblast invasion to transform maternal spiral arteries resulting
in a poorly-perfused and poorly developed placenta has also been associated with IUGR
but to a lesser extent.4,12,13 One consistent finding on the other hand, is the
histopathological evidence of placental ischemia and oxidative stress in placentae from
both IUGR and PE pregnancies.13-16 Common histopathological features include: villous
infarctions, fibrin deposition, and syncytial knotting.14-16 This provides evidence for some
common underlying pathophysiological mechanisms in the placenta in PE and IUGR.
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Figure 1.2 Schematic depicting normal and abnormal trophoblast invasion.
Trophoblast invasion is a process necessary to increase maternal blood flow into the
uteroplacental unit to support gas and nutrient exchange for pregnancy. The left panel
depicts normal trophoblast invasion, where extravillous CT cells differentiate further into
endovascular CT cells which remodel maternal spiral arteries by replacing maternal
endothelial cells, this also results in dilation of maternal arteries. This process occurs in
the presence of maternal immune cells including uterine natural killers (uNK) cells and
macrophages. The right panel depicts abnormal trophoblast invasion, represented by
failure of trophoblast cells to migrate and invade spiral arteries. Subsequently, spiral
arteries remain undilated and under maternal vasomotor control as trophoblast cells fail to
replace maternal vascular endothelial cells. This results in decreased perfusion of
maternal blood into the intervillous space.
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1.2
1.2.1

DOHaD and Epigenetic Regulation
Developmental origins of health and disease hypothesis (DOHaD)

Infants exposed to intrauterine stress during pregnancy, particularly growth restricted and
preterm infants are at higher risk for perinatal morbidity and adult onset diseases.17 This
is recognized through the “developmental origins of health and disease” (DOHaD)
hypothesis, which states that alterations from a normal environment during critical and
sensitive periods of growth and development result in gene expression changes in the
fetus, which lead to changes in fetal phenotype including birth weight and predisposition
to disease later on in life.17 Fetal programming is the term used to refer to the genetic and
epigenetic changes occurring in utero in response to adverse environmental signals.17,18
Due to the placenta’s pivotal role in regulating and supporting fetal growth it is directly
involved in fetal programming in early life.18-20
Placental dysfunction is a feature of pregnancies that lead to fetal programming effects,
most commonly identified in IUGR pregnancies.18,20 However, programming effects are
also observed in preterm births, PE, and uncontrolled gestational diabetes.18,20
Pathologies in the placenta such as maldevelopment of villous trees, impaired
vasculogenesis, poor syncytiotrophoblast repair and accumulation of syncytial knots,
directly impact placental function.18-20 Most importantly pathologies in the placenta will
impact nutrient and oxygen delivery to the fetus and the synthesis and regulation of
hormones necessary for fetal and placental growth.19,21 The placenta must also adapt to
maternal signals including maternal hormones, nutrition, and BMI.19,21 Therefore,
investigation of genetic and epigenetic changes in the placenta, particularly changes
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involved in disease pathophysiology, is important to expand our understanding of the role
of the placenta in fetal programming in utero.

1.2.2

Epigenetics

Epigenetic mechanisms are mechanisms that regulate gene expression without changes to
the underlying DNA sequence.22,23 The profile of epigenetic modifications of a cell,
although often identified through studying the tissue, is identified as the epigenome.24
Epigenetic marks are also heritable through cell division and are plastic, these
characteristics are observed through transgenerational inheritance of epigenetic marks
and changes in response to environmental signals.23,24 Research has identified a number
of epigenetic mechanisms including DNA methylation, histone modifications and noncoding RNAs (Figure 1.3).22,23
DNA methylation involves the covalent transfer of a methyl group to the C-5 position of
the cytosine ring via enzymes called DNA methyltransferases (DNMT).22,23 Methylation
commonly occurs in cytosine-guanidine (CpG) rich regions.22,23 Regions of the genome
with high CpG content are identified as CpG islands and can be found in gene promoter
regions.22,23 Islands associated with gene promoters are important sites of regulation
where methylation can result in gene silencing by suppressing transcription, and the
reverse, the removal of a methyl group will activate transcription and gene
expression.22,23 In recent studies, the role of hydroxymethylated cytosines (5-hmC) as an
epigenetic mark has also been studied.25 5-hmC differs from methylated cytosines in that
there is an additional hydroxyl group.25 Initially 5-hmC was thought to be an intermediate
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step in demethylation, but now it is hypothesized that in fact it has a role in regulating
gene expression.25 Chromatin is composed of nucleosomes which consist of DNA
wrapped around histone proteins.22,23 The DNA-protein complex is subject to covalent
modification via the exposed N-terminal tail of the histone protein.22,23 Modifications
include phosphorylation, methylation, acetylation and ubiquitinylation, and each
modification can result in either transcriptional activation or repression.22,23 Similar to
DNA methylation, histone modifications require enzymes called histone transferases.22
There are well studied histone modifications for transcriptional activation such as histone
acetylation or di-/tri-methylation of lysine 4 of histone 3.22 Meanwhile di-/tri-methylation
of lysines 9 or 27 of histone 3 leads to transcriptional repression.22 Parts of the genome
encoding non-coding RNAs (ncRNAs), including miRNAs were once considered junk
DNA. Advancements in research later showed these regions of the genome are
transcriptionally active but are not translated into proteins. These transcribed ncRNAs
were found to be important regulators of many developmental processes. NcRNAs are
classified into categories based on length and function. The most common categories are
long non-coding RNAs (lncRNA), small interfering RNAs (siRNA) and microRNAs
(miRNA) which are RNAs processed from primary transcripts in the nucleus and can
alter gene expression by binding to the mRNA of the target gene in the cytoplasm.22,23
Epigenetic regulation of gene expression in the placenta during this critical period of
development plays a direct role in fetal programming.23,24,26
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Figure 1.3 Epigenetic mechanisms that can alter gene expression without changes to the
underlying DNA sequence.

1.2.3

MicroRNAs

MiRNAs were originally described in the nematode C. elegans, and then later discovered
in the genomes of plants and animals.27 MiRNAs can regulate gene expression by binding
to the target mRNA resulting in degradation or halting protein translation.27,28 The first
step in miRNA biogenesis is transcription by RNA polymerase II into a looped, hairpinshaped, primary miRNA (pri-miRNA).27,28 A RNase III endonuclease called Drosha
enzymatically cleaves pri-miRNA, with guidance from DGCR8 and RNA binding
proteins, into a stem-looped precursor miRNA that is 60-70 nucleotides long. Precursor
miRNAs are transported into the cytoplasm through exportin 5, as the name suggests an
exporter on the nuclear membrane.27,28 In the cytoplasm, a second cleavage event by
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dicer, also an RNase III endonuclease, releases the loop and results in a mature miRNA
duplex that is 20-22 nucleotides in length.27,28 The double stranded miRNA then binds
RISC (RNA-induced silencing complex) and is unwound, the guide strand remains
attached to RISC and the passenger strand is degraded.27,28 Argonaute 2 (AGO2) and
GW182 are core RISC members and with help of accessory proteins they facilitate
miRNA targeting.27-29
Complementarity of the miRNA to the mRNA determines the fate of the mRNA. A 6-7
nucleotide region of the miRNA identified as the seed region targets the 3ˈUTR of the
mRNA.30 Interactions between mRNAs and miRNAs at the seed regions have been
categorized into three canonical site types (1) 7mer-A1: 6 nucleotide seed match plus
adenosine at position 1, (2) 7mer-m8: 6 nucleotide seed match plus a match at position 8 ,
and (3) 8mer: 6 nucleotide seed match plus a match at position 8 and adenosine at
position 1.30 Perfect complementarity between the miRNA seed region and the 3ˈUTR of
the mRNA will target the mRNA for degradation by cleavage.27-30 This process is
mediated through the GW182 recruitment of poly-A binding protein (PABP) which
subsequently recruit deadenylases CCR4 and CAF1.27-30 Mismatch between the miRNA
seed region and the 3ˈUTR of the mRNA will result in translational repression through
RISC’s recruitment of accessory proteins that will prevent translational machinery from
translating the mRNA into a protein.28-30
MiRNA biogenesis and function are complex processes that involve large networks of
proteins that remain under investigation today. For example the miRNA duplex that
forms in the cytoplasm as a result of dicer cleavage contains a guide strand and a
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passenger strand, and the proper miRNA nomenclature now refers to the two strands as 3p and -5p respectively.30,31 Although it was once thought that only the -3p strand exerted
biological functions, recent evidence shows that the -5p strand can also be the “guide
strand”.31 However, the process by which this is regulated remains under investigation.
Even with the complexities of these processes, miRNAs have been shown to regulate
large numbers of target mRNAs and are estimated to potentially regulate 60% of genes in
eukaryotic genomes.32,33 MiRNAs have also been implicated in diseases such as cancer,
diabetes, cardiovascular disease and pregnancy complications.34

1.3
1.3.1

Epigenetic regulation in the placenta
DNA methylation

DNA methylation is one of the more extensively investigated epigenetic regulatory
mechanisms in the human placenta. The placental methylome has been investigated in the
normal human placenta across gestation, in different placental cell types, in pregnancy
complications, and in its response to environmental signals.24,26,35 During the preimplantation phase, the fertilized ovum undergoes an erasure of methylation marks and
by the blastocyst stage, the genome is almost entirely hypomethylated, with the exception
of imprinted genes, which are genes expressed mono allelically in a parent-of-origin
dependent manner.36,37 After differentiation into the ICM and the trophectoderm, de novo
methylation takes place but is restricted to the ICM, while the trophectoderm, which
gives rise to the placenta remains virtually hypomethylated.37,38
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Studies have shown that the placental genome remains hypomethylated compared to
somatic tissues and cells.39,40 Global methylation levels are also shown to increase across
gestation, from first to third trimester, however this could potentially be attributed to
changes in cell composition in response to progress of gestation.40,41 A landmark study by
Schroeder et al. in 2013, showed that the global hypomethylated profile of the placenta is
organized into partially methylated regions (PMDs), which are large contiguous domains
(> 100 kb) that have reduced DNA methylation and cover 40% of the placental genome.42
Genes in the placenta found within PMDs are repressed, as confirmed by RNA-seq, have
tissue-specific functions and demonstrate stability across gestation.42 Interestingly,
methylation at promoter CpG islands was more commonly found in the genes that fall
within PMDs, which is a possible explanation for the repressed state of these genes.42 In
total, 3,815 genes were identified to overlap PMDs providing evidence for epigenetic
regulation of gene expression in the placenta.42
Since the placenta is composed of several cell types, it is important to consider that each
cell type can have unique epigenetic marks that contribute to the epigenetic profile of the
placenta. Indeed, studies have shown differences in DNA methylation between placental
CTs and fibroblasts (at 442 CpGs), and in comparing methylation in each cell type to
whole placental villi samples.43 Other studies have shown differences in DNA
methylation in CT and SCT cells, with potential functional implications since
differentially methylated regions in EVT cells are enriched for genes important for
invasion and proliferation.44-47
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Epigenetic regulation via DNA methylation in human placentae from complicated
pregnancies such as PE, IUGR, gestational diabetes and pre-term births is also being
extensively researched. In PE pregnancies, one study identified a significant overall
increase in global methylation in PE placenta compared to controls.48 The same study
noted a positive association between global methylation levels and maternal
systolic/diastolic pressure.48 PE has also been associated with altered methylation of a
subset of genes, including but not limited to, TIMP5349, SERPINB550 and SERPINA351,52,
and 11bHSD53. In IUGR, an early study identified 22 genes with differential methylation
between control and diseased placentae, some with reduced and some with increased
methylation.54 Down-stream analysis revealed those genes are implicated in Huntington’s
disease, Alzheimer’s disease and protein export.54 A more recent study identified no
differentially methylated positions between IUGR placenta and control (term) placenta.55
The placental epigenome is also plastic, this is evident from studies observing changes in
DNA methylation in response to environmental exposures.56-58 Collectively, these
findings provide evidence for the presence of epigenetic regulation via DNA methylation
in the human placenta, and its direct role in placental growth and function, and
subsequently fetal programming.

1.3.2

Non-coding RNAs

1.3.2.1 Long Non-coding RNAs in the placenta
Long non-coding RNAs (lncRNAs) are widely expressed in the human genome and
recent advancements in NGS technology allow for identification of novel lncRNAs
implicated in development and disease. lncRNAs are > 200 nucleotides in length and
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have a diverse range of molecular functions.59,60 In the placenta, dysregulation of
lncRNAs is reported in PE, IUGR and other placenta related complications.61-65
H19 is a commonly investigated lncRNA located within a large imprinted region on
chromosome 11, 130 kb downstream of IGF2.66 H19’s reported functions include a
modulator for binding small RNAs and proteins, and a source of miR-675.67,68 In the
placenta H19 expression is restricted to the intermediate and villous cytotrophoblasts and
is thought to regulate the invasive properties of trophoblast cells.69,70 In EO-PE placenta
the H19 promoter region is hypermethylated and is correlated with decreased H19
expression.63,71 Altered H19 and IGF2 expression has also been reported in placenta from
IUGR and SGA pregnancies.63,65,72 In placenta from IUGR pregnancies there is partial
loss of imprinting (LOI) with biallelic expression of H19.65 MALAT1 is another lncRNA
with reported decreased expression in PE placenta compared to controls.62 MALAT1
expression has been shown to increase invasion and migration in trophoblast cell
lines.62,73 Interestingly MALAT1 expression is increased in placenta increta and in
contrast to shallow invasion in PE, placenta increta is overly invasive.73 Ongoing
discovery and characterization of novel and known lncRNAs is important to increase our
understanding of this mechanism in placental development and disease.
1.3.2.2 MicroRNAs in the placenta
MiRNAs are widely expressed in normal human tissues and can exhibit tissue
specificity.74 In the placenta, two miRNA clusters are predominantly expressed and are
only conserved in mammals, C19MC and C14MC, chromosome 19 and 14 miRNA
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clusters, respectively.75,76 The C19MC cluster is located at 19q13.41, it spans ~ 100 Kb of
genomic DNA, and is one of the larger miRNA clusters identified to date.75,76 This
primate-specific cluster contains 46 pre-miRNAs expressed exclusively from the paternal
allele, and produces 58 mature miRNAs.75,76 Functionally, C19MC expression is reduced
in human EVT cells compared to VT cells, and expression of the C19MC attenuated
migration of human EVT cells in vitro.77 Directly adjacent to the C19MC is a small
cluster known as the miR-371-3 cluster, which is also conserved in mammals and
predominantly expressed in the placenta.75,76 The miR-371-3 cluster includes three
miRNAs and spans 1050 bp.75,76 The C14MC cluster is located at 14q32, it spans ~ 40 Kb
of genomic DNA, and it harbors 52 miRNA genes expressed exclusively from the
maternal allele, and produces 63 mature miRNAs.78 Specific functions for the C14MC
have not yet been identified in the placenta.
The main source of miRNAs in the placenta is trophoblast cells, therefore ongoing
research is focused on the role of miRNAs in trophoblast functions.76 One example is the
miR-17 ~ 92 miRNA cluster that has been shown to regulate trophoblast differentiation
by targeting important proteins such as CYP19A1(aromatase) and the transcription factor
GCM1.79 Studies have identified differential expression in miRNAs between first and
third trimester control human placenta, alluding to the potential role of miRNAs in
placental development.76,80 A study by Gu et al. (2013), identified 191 mature miRNAs to
be differentially expressed between first and third trimester placental villous samples.80 In
addition, miRNAs within the C19MC, C14MC, and the miR-371 clusters are upregulated
in first trimester samples compared to third trimester samples.80 MiRNAs that are highly
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expressed in the first trimester are related to angiogenic, oncogenic and anti-apoptotic
function, whereas, miRNAs expressed in the third trimester are related to cell
differentiation and tumor suppression functions.80 Interest in investigating the role of
placental miRNAs in placental growth, function, and particularly disease was further
increased with discovery of placental miRNAs in maternal circulation.81 A study by Luo
et al. (2009) identified exosomes as a mechanism of entry for placenta-specific miRNAs
originally expressed in trophoblast cells into maternal circulation.81
1.3.2.3 MicroRNAs in maternal circulation
Early studies measuring miRNA expression in maternal plasma utilized cell-free RNA. 82
Later studies show that placenta-specific miRNAs can enter maternal circulation via
exosomes, extracellular vesicles 40-120 nm in size involved in cell-cell signaling and
communication.81 Protocols for isolation and purification of trophoblast-specific
exosomes from maternal plasma have been challenging and most current studies continue
to utilize cell-free RNA. One of the earliest studies conducted by Chim et al. (2008),
assessed the expression of 157 miRNAs in maternal plasma from pregnant women, and
identified four miRNAs that were highly expressed (miR-141, miR-149, miR-299-5p,
miR-135b).82 Further studies investigated the expression of C19MC in maternal plasma
of pregnant women compared with non-pregnant women. Seven miRNAs (miR-516-5p,
miR-517, miR-518b, miR-520a, miR-520h, miR-525 and miR-526a) were identified as
new pregnancy associated miRNAs with diagnostic potential.83 Some of these miRNAs
have also been identified in maternal plasma by other studies, such as miR-517 and miR518.84 However, expression levels of miRNAs in maternal plasma can be confounded by
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the mode of delivery. In a study by Morisaki et al. (2015), levels of placenta-specific
miRNAs such as miR-515-3p, miR-517a/c, and miR-518b are significantly higher in the
patient group that had undergone labor compared to the non-labor group.85
More recent studies have focused on the detection of miRNAs in the plasma of women
diagnosed with PE and/or IUGR, to identify miRNAs with diagnostic potential. The
levels of ten C19MC miRNAs were found to be significantly elevated in maternal plasma
from patients with severe PE.86 In first trimester maternal plasma samples a predictive
value for miR-517-5p, miR-518b, and miR-520h with PE was identified.87 Increased
expression of these miRNAs was observed in first trimester plasma samples from women
who developed PE later in pregnancy compared to normal pregnancies.87 The same
subset of miRNAs was assessed for their predictive value of IUGR, but no associations
were identified.87 Another study by Hromadnikova et al. (2016) comparing maternal
plasma samples from PE and IUGR pregnancies to control pregnancies, identified
downregulation of miR-100-5p, miR-125b-5p, and miR-199a-5p.88 Although many
miRNAs have been identified in maternal plasma from PE and IUGR pregnancies,
currently, there is no agreed upon subset of miRNAs associated with either PE or IUGR
with promising diagnostic potential. This can be attributed to differences in patient
populations and approaches to miRNA quantification, however research on the potential
use of miRNAs as a diagnostic or predictive tool for pregnancy complications remains
ongoing.
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1.4

Rationale

The placenta performs important functions during pregnancy and it is key player in fetal
growth and development.1,2,4,5 Pregnancy complications such as PE and IUGR implicate
the placenta in disease etiology.6,7 The placenta must also adapt to maternal stimuli such
as poor nutrition, obesity and preexisting medical conditions.18-21 This directly implicates
the placenta in fetal programming.18,21 There is accumulating evidence for the presence of
epigenetic mechanisms in the placental genome, in addition to evidence of differential
epigenetic regulation during pregnancy complications that may contribute to fetal
programming.42,48,59,60 This study aims to investigate miRNA and gene expression in a
matching sample set of well-defined patient groups with early-onset pregnancy
complications to expand our understanding of miRNA function in the placenta in the
pathophysiology of diseases with placental origins. Due to the common overlap of PE
and IUGR in early-onset patients12, we segregated patients into 3 groups: PE only, IUGR
only, and PE+IUGR to identify similarities and differences.

1.5

Hypothesis and Objectives

MicroRNAs are differentially expressed in diseased placentae obtained from pregnancies
complicated by early-onset intrauterine growth restriction (IUGR) and/or preeclampsia
(PE) and they regulate downstream gene targets involved in the growth/development and
functions of the placenta.
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This hypothesis will be addressed in the following 3 objectives:
1.

Conduct miRNA expression analysis in placental samples from early-onset (EO)
IUGR, EO-PE, as well as pregnancies complicated by both EO-PE and EO-IUGR

2.

Conduct gene expression analysis in the same placental samples from EO-IUGR,
EO-PE, as well as EO-PE+IUGR, and investigate downstream impact of miRNA
dysregulation

3.

Transfect a trophoblast cell line with miRNA mimics and inhibitors to investigate
the functional impact of miRNAs in vitro

1.6
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Chapter 2

2

Placental microRNAs in pregnancies with early onset
intrauterine growth restriction and preeclampsia: Potential
impact on gene expression and pathophysiology1

2.1 Introduction
Abnormal placental development in pregnancy may result in complications such as
preeclampsia (PE) and intrauterine growth restriction (IUGR).1,2 PE is a maternal
hypertensive disorder occurring in 2-8% of pregnancies worldwide.3,4 Intrauterine growth
restriction is poor fetal growth in utero with an expected fetal weight lower than the 10th
percentile estimated for gestational age and gender, and can be associated with abnormal
Dopplers in fetal and umbilical vessels.5,6
PE and IUGR are heterogeneous in etiology and can be attributed to maternal, fetal
and/or placental factors. Maternal risk factors associated with PE include maternal
diabetes, pre-existing hypertension, renal disease and obesity.4 Some of these maternal
risk factors have also been associated with IUGR.5 IUGR is also associated with fetal risk
factors such as chromosomal abnormalities, congenital anomalies and infection.5,6 A
subset of patients develop early-onset PE together with IUGR, suggesting an overlap in
the etiology underlying these complications. Histopathology of placentae from PE and
IUGR pregnancies shows similar microscopic placental abnormalities, supporting the
concept of similar pathophysiology underlying these two disorders.7
1
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Although the gestational age of the onset of signs and symptoms of either PE or IUGR is
based on clinical outcomes and there is some overlap, it is now recognized that the earlyand late- onset forms of the diseases may have different pathophysiology.8 Early-onset
forms of these complications are more severe, where the mother and infant are at higher
risk of short- and long-term adverse health outcomes.6,9 In particular, the newborns are
usually born prematurely and are impacted by the morbidity of preterm birth.
Placental micro(mi)RNAs have been investigated for their role in the growth and function
of the placenta, and for their potential use as diagnostic biomarkers due to their ability to
enter the maternal circulation and are detectable in maternal plasma.10 MiRNAs are a
class of non-coding RNAs that are tissue-specific and are encoded in the human
genome.11,12 MiRNAs anneal to the 3`UTR of target mRNAs via sequence
complementarity, and either transiently block mRNA translation or degrade the mRNA,
this classifies miRNAs as epigenetic regulators.11,12 The final product of miRNA
biogenesis is an 18-22 base pair, single nucleotide strand, transcribed in the nucleus and
then transported into the cytoplasm.11,12 Placenta-specific clusters have been identified on
chromosomes 14 and 19.13,14 Differential expression analysis of miRNAs in the placenta
revealed changes in miRNA expression in placentae from pregnancies complicated with
PE and IUGR.15,16 The most consistent finding is the increased expression of hypoxiainducible miR-210 in PE placentae.15 However, there are differences in findings among
previous studies that can be attributed to: (i) the definition of patient groups; (ii)
differences in the platforms used to measure expression; and (iii) analytical methods used
to identify differentially expressed miRNAs.
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The objective of this study was to utilize next-generation sequencing (NGS) to identify
miRNAs and genes (mRNAs) expressed in the same placental tissues from three patient
groups with early-onset placental disease. The patient groups include: PE only, IUGR
only, PE + IUGR, and gestational-age matched controls without PE or IUGR. This
analysis aims to identify differentially expressed miRNAs and genes in each disease
group compared to the control group, and to integrate the two expression datasets to
identify potential gene targets regulated by miRNAs.

2.2
2.2.1

Materials and Methods
Patient Recruitment

Preeclampsia was defined as hypertension (blood pressure > 140/90 mm Hg) and
proteinuria (³ 300 mg in 24 hours).3,4 Severe PE is often associated with HELLP
syndrome characterized by the onset of: edema, headache, elevated liver enzymes, and
low platelet count. Patients diagnosed with PE and HELLP are indicated in Table 2.1.
Intrauterine growth restriction was defined as estimated fetal weight below the 10th
percentile for gestational age and gender, associated with abnormal umbilical and uterine
artery Dopplers.5,6 Patients with PE + IUGR presented with criteria aforementioned for
both diseases. Only patients diagnosed prior to 34 weeks (early-onset) were included in
this study. Patients with preterm labor and no other pregnancy complications before 34
weeks of gestation were recruited as controls. Women with diabetes, gestational diabetes,
pre-existing hypertension, obvious chorioamnionitis (status confirmed at delivery),
alcohol/drug use, chromosomal or genetic abnormalities, congenital anomalies, or
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infection were excluded. All women enrolled in this study gave written informed consent
for the collection of samples and information. This research was approved by the office
of Human Research Ethics at Western University (REB # 102621).

2.2.2

Placental Tissue Sampling

Samples were collected from two central and two peripheral portions of the placenta
within 30 minutes of delivery. Central samples were collected within a 5 cm radius from
the umbilical cord insertion site and the peripheral samples were collected 2-3 cm from
the edge of the placenta. Full depth 1 cm x 1 cm tissue samples were excised, and the
maternal decidua was separated from the chorionic villi using gross dissection. In this
study, the maternal and fetal components were separated and only the fetal components
(chorionic villi) were used for analysis. The tissue samples were flash frozen in liquid
nitrogen and stored at -80°C until further analysis.

2.2.3

RNA Isolation and Sequencing

Total RNA was isolated from 80-100 mg of tissue samples from each of the four regions
of each placenta using the mirVana RNA isolation kit (Life Technologies, Waltham, MA,
USA). Sample quantity and quality was checked using the Agilent Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA, USA). Total RNA isolated from central and
peripheral samples of each placenta was pooled in equal quantities for one representative
total RNA sample from each patient. Samples were then sent to the Génome Québec
Innovation Centre at McGill University (Montreal, QC, Canada) for library preparation
and sequencing. The Illumina Truseq RNA and smRNA library preparation kits were
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used to prepare mRNA and miRNA libraries respectively (Illumina, San Diego, CA,
USA). Samples were sequenced on the Illumina HiSeq 2000. Complete sample journey is
depicted in Supplementary Information: Figure 2.7.

2.2.4

Differential Expression Analysis

Raw read files were received from Génome Québec, FastQC was used to assess read
quality. For miRNA data, sequences were aligned to miRBase version 21 index and for
mRNA data, sequences were aligned to the transcriptome (GRCh37/hg19), both aligned
using Bowtie2. In R v3.3.1,17 three Bioconductor packages were used for differential
expression analysis, DESeq218 (Benjamini-Hochberg adjusted p-value < 0.01), edgeR19
(Benjamini-Hochberg adjusted p-value < 0.01) and ALDEx220 (effect > 0.8). Samples
that contributed at least the median plus twice the inter-quantile range (IQR) of variance
to the group were considered outliers and were subsequently removed from the
analysis.21 Only miRNAs and genes identified by at least two programs were considered
significant. To adjust for covariates (fetal sex, maternal BMI, gestational age,
chorioamnionitis, and mode of delivery (labor/no labor, C-section/vaginal)), surrogate
variable analysis (SVA R version 3.6)22 was used with DESeq2 and edgeR. The miRNA
and gene expression data are available from the Gene Expression Omnibus (GEO)
database under accession numbers GSE114349 and GSE114691, respectively.

2.2.5

Validation of miRNAs using qRT-PCR

Total RNA was reverse transcribed using TaqMan advanced miRNA cDNA synthesis kit
(Life Technologies, Waltham, MA, USA). Quantification of miRNAs was completed
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using the TaqMan fast advanced PCR master mix in conjunction with TaqMan miRNA
expression assays (Life Technologies, Waltham, MA, USA). For miRNA normalization,
miR-191-5p was used as an endogenous control.23,24 The DDCt method was used for foldchange analysis. Mann-Whitney-U test was used for statistical analysis.

2.2.6

Target Prediction and Gene Ontology

Spearman correlation co-efficient was used for correlation analysis between miRNA and
gene expression values. Only correlation with a rs £ -0.5 and p-value £ 0.01 was
considered significantly negatively correlated. To further refine results only genes with a
fold-change £ -1.5 were included for target prediction analysis. Two target prediction
software were used: TargetScan (v7.1)25 and DIANA-microT-CDS (v5.0)26. Criteria used
for final selection of miRNA gene targets are in Supplementary Information: Table 2.2.
Gene ontology analysis was completed using WebGestalt (2013)27.

2.3
2.3.1

Results
Patient selection criteria and principal component analyses

Our aim was to select patients with primarily placental factors underlying the pregnancy
complication, therefore stringent inclusion and exclusion criteria were used in the patient
recruitment into the study. Patients with known maternal and/or fetal risk factors were not
included (see methods). Clinical characteristics of the patient cohorts are described in
Table 2.1.
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Preliminary exploratory analysis of the miRNA and gene expression datasets had two
aims: identification of outliers and principal component analysis (PCA) to determine if
the samples clustered by disease. Identified outliers were removed prior to PCA. Based
on miRNA expression data sets, one patient each was removed from the PE only group
(N=19) and from the control group (N=20). Two patients were removed from the IUGR
group (N=16), and none were removed from the PE + IUGR group (N=20). Based on the
gene expression data set, one patient was removed from the PE only group (N=19), three
patients from the IUGR only group (N=15), and four patients from the PE + IUGR group
(N=16). None were removed from the control group (N=21).
Principal component analysis was then used to determine how patient samples cluster
based on the expression data. Based on expression of all known human miRNAs, samples
clustered separately based on disease status on the first principal component (Figure 2.1
a-c). Based on the transcriptome, samples also clustered separately based on disease
status on the first principal component (Figure 2.1 d-f). Patients with PE and IUGR
clustered away from controls with 15 - 40% of the variance in the data explained by the
first principal component.
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Table 2.1 Clinical characteristics of patients with complicated pregnancies and
gestational age-matched controls.

1) p-value < 0.05 vs. control 2) p-value < 0.001 vs. control 3) p-value <0.0001 vs. control 4) p-value <0.01
vs. PE only 5) p-value < 0.0001 vs. IUGR only
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Figure 2.1 Principal Component Analysis (PCA) Plots.
PCA demonstrates clustering of patient samples based on miRNA expression (a-c) or
gene expression (d-f). Gestational age-matched controls are indicated in open circles and
diseased groups are indicated in closed circles. A, D. Preeclampsia B, E. Intrauterine
growth restriction C, F. Preeclampsia and intrauterine growth restriction.
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2.3.2

Differential expression analysis of placental microRNAs

To identify differentially expressed miRNAs in each patient group compared to
gestational-age matched controls, three different programs namely DESeq2, edgeR, and
ALDEx2 were used. Only miRNAs identified by at least two were considered significant.
Using DESeq2 and edgeR, we accounted for covariates in the model such as fetal sex,
maternal BMI, gestational age, and mode of delivery. We identified 11 up-regulated
miRNAs in the PE only samples (Figure 2.2a), 25 upregulated and 12 downregulated
miRNAs in IUGR only samples (Figure 2.2b), and 9 upregulated miRNAs in PE + IUGR
samples (Figure 2.2c) (Supplementary Information: Table 2.3). Comparison of all
differentially expressed miRNAs revealed 6 miRNAs that are common to all three patient
groups (Figure 2.3a). All of the differentially expressed miRNAs were confirmed using
qRT-PCR, with the exception of miR-520a-3p in the IUGR group (Figure 2.3b).
Similarly, 3 miRNAs that were common to patients with PE only (Figure 2.3a) were also
validated using qRT-PCR (Figure 2.3c).

Figure 2.2 Heat maps depicting differentially expressed microRNAs in each patient group
Differential expression analysis revealed 11 upregulated miRNAs in A. Preeclamptic placenta, 25 upregulated and 12 downregulated
miRNAs in B. Intrauterine growth restricted samples, and 9 upregulated miRNAs in C. Preeclamptic and Intrauterine growth
restricted samples. Three programs were used for differential expression analysis, and only miRNAs identified by two or more
programs were included in the final results.
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Figure 2.3 Comparing differentially expressed microRNAs between patient groups.
A. Six miRNAs are found to be common to all three patient groups, whereas three
miRNAs are specific to patients with PE. B. Validation of miRNAs common to all three
patient groups (with the exception of miR-520a-3p in the IUGR only group), and C.
miRNAs common to PE patients using qRT-PCR. To find relative expression, the DDCT
method was used and values were normalized to hsa-miR-191-5p expression. Data is
shown as the mean ± SEM, significant differences were determined by a Mann-Whitney
U test. **p-value< 0.01
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2.3.3

Differential gene expression analysis in the same patient groups

The same differential expression analysis methods used for the miRNA dataset were
applied to the gene expression dataset. In total, there were 275 differentially expressed
genes in the PE only samples, 155 differentially expressed genes in the IUGR only
samples, and 556 differentially expressed genes in PE + IUGR samples (Supplementary
Information: Table 2.4). Top ten up- and down- regulated genes in each disease group are
shown in Figure 2.4 (a-c). Comparison of differentially expressed genes in all patient
groups revealed 22 differentially expressed genes in placental samples from all three
disease groups (Figure 2.5). Other genes showed specificity to patients with PE or
patients with IUGR, with 141 and 21 differentially expressed respectively. Lists of
common genes between patient groups are found in Supplementary Information: Table
2.5.

Figure 2.4 Heat maps depicting top differentially expressed genes in each patient group
Top ten upregulated and ten downregulated genes after differential expression analysis revealed A. 275 genes in PE only placenta, B.
155 genes in IUGR only placenta, and C. 556 genes in PE + IUGR placenta. Three programs were used for differential expression
analysis, and only genes identified by two or more programs were considered differentially expressed.
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Figure 2.5 Comparing differentially expressed genes between patient groups
A. Venn diagram shows the number of differentially expressed genes in each patient
group compared to the control group. Three programs were used for differential
expression analysis (DESeq2, edgeR, ALDEx2), and only genes identified by two or
more programs were considered differentially expressed. B. This analysis revealed 22
genes common to all three patient groups.
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2.3.4

Target Prediction and gene ontology analyses

As epigenetic regulators abundantly expressed miRNAs can impact gene expression by
targeting mRNAs in the cytoplasm. Inverse correlation analysis using Spearman’s
correlation co-efficient identified genes that were negatively correlated in expression to
differentially expressed miRNAs. Some identified genes had a significant negative
correlation with one or more miRNA. To further refine the results, only candidate genes
with fold-change (£ -1.5 or ³ 1.5) were selected for further analysis. Target prediction
software programs (DIANA-microT-CDS and TargetScan) were used to identify
predicted gene targets for miRNAs. A summary of criteria used to select appropriate gene
targets is found in Supplementary Information: Table 2.2. This analysis resulted in 16
candidate gene targets (Figure 2.6a) (Supplementary Information: Table 2.6). The
majority of candidate gene targets identified were found in PE only or PE + IUGR
groups. Interestingly, there were candidate genes such as APLN, CSF1, FZD5, and
TYRO3 that are potential targets of multiple miRNAs (Figure 2.6a). Gene ontology
analysis of the 16 candidate gene targets revealed that most genes are involved in
important cellular functions including proliferation, migration, communication and
adhesion (Figure 2.6b).

46

Figure 2.6 Target prediction and gene ontology analyses.
A. Identified candidate gene targets for miRNAs that have been validated with qRT-PCR.
Spearman correlation was used to identify genes that inversely correlate in expression to
validated miRNAs, in each patient group. Candidate gene targets were identified using
prediction software DIANA-microT-CDS and TargetScan. B. Gene ontology analysis for
identified candidate genes.
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2.4

Discussion

Our study identified dysregulated miRNAs and genes in placental samples that are
common to three patient groups with early-onset pregnancy complications. More
specifically, 6 miRNAs and 22 genes were found to be commonly differentially
expressed in patients with early-onset PE, IUGR, and PE + IUGR, compared to
gestational age matched controls. However, some miRNAs and genes remained disease
specific. To integrate the miRNA and gene expression datasets, inverse correlation
analysis revealed candidate gene targets primarily involved in cell functions such as
proliferation and migration.
MicroRNAs identified to be common to all patient groups, are some of the most
commonly identified miRNAs in the literature. MicroRNAs identified in this study have
been identified in studies measuring miRNA expression in placental samples from
primarily PE pregnancies. Studies assessing global miRNA expression in placenta from
IUGR pregnancies are scarce, potentially due to heterogeneity of etiologies underlying
this condition. Studies utilizing global miRNA expression analyses in PE placenta with
overlapping findings to this present study are found in Supplementary Information: Table
2.7. One of the most well characterized miRNAs in pregnancy complications is miR210.15,28 Under hypoxic conditions, miR-210 is upregulated by the transcription factor
HIF-1a.28 The intrauterine environment in pregnancies complicated by PE and/or IUGR
has been suggested to be hypoxic due to decreased perfusion of maternal blood to the
feto-placental unit. In our study, we identified that miR-210-3p is common to all patient
groups, whereas miR-210-5p is common to patients with PE (Figure 2.3). Gene targets of
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miR-210 have also been investigated to identify the impact of the upregulation of miR210 on the placenta during disease.28 Identified targets for miR-210 include EFNA3 and
HOXA9, which are important for cell functions such as migration and invasion.28,29 In our
study, downregulated predicted targets of miR-210-5p are also involved in cell migration,
they include APLN, CSF1, ITGAM, C3AR1, and SELE (Figure 2.6, Supplementary
Information: Table 2.6). These novel gene targets for miR-210-5p have been identified to
be downregulated in patients with preeclampsia (± IUGR) in our study (Supplementary
Information: Table 2.4). Gene targets such as APLN and C3AR1 have been shown in the
literature to be downregulated in placental samples from PE patients with an unknown
underlying mechanism for dysregulation. 30,31
Other miRNAs such as miR-193b-3p/5p, and miR-365a/b-3p have also been previously
identified in studies measuring miRNA expression in placental samples from PE
pregnancies32-34 (Table 2.7). Identified gene targets for miR-193b-3p/5p are enriched in
gene ontology categories important for cell functions such as cell proliferation, adhesion,
and migration (Figure 2.6a). Zhou et al. (2016) showed increased expression of miR193b-3p and -5p in PE patients, and that miR-193b-3p was found to decrease migration
and invasion of HTR-8/SVneo cells.34 We also identified FZD5 (frizzled 5) as a
candidate gene target for miR-365a/b-3p, which belongs to the frizzled family of
proteins, known to be important during placental development (Figure 2.6). Frizzled 5
mRNA and protein have also been reported to be down regulated in PE placenta.35 In the
IUGR only group the majority of miRNAs remained unique to that patient group (31/37).
Only 2 miRNAs overlap with findings in the literature, however, in the opposite direction
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of expression. In our study miR-515-5p and miR-519d-5p were upregulated, and in the
study by Higashijima et al. that utilized NGS these two miRNAs are downregulated.16
Interestingly, of the 37 differentially expressed miRNAs in the IUGR only group, 4
belonged to the C19MC (520a-3p, 520f-5p, 515-5p, 519-5p) and 6 belonged to the
C14MC (299-3p, 494-3p, 376a-5p, 382-3p, 154-3p, 369-3p), the two miRNA clusters
known to be placenta-specific.1
Differential gene expression analysis in placentae from the same patient populations, was
crucial in identifying potential gene targets for the validated miRNAs. In addition,
comparison of all patient groups revealed a subset of genes common to the three diseased
patient groups. A number of the differentially expressed genes the we have identified in
our diseased patient cohorts, have previously been identified to be dysregulated in
placental samples from complicated pregnancies. One example includes INHA (inhibin)
and FSTL3 (follistatin-like 3), both of which have been reported to be upregulated in PE
placenta.36,37 In this study INHA and FSTL3 are upregulated in pregnancies with IUGR as
well (Figure 2.4, Supplementary Information: Table 2.4). Differences observed between
this current study and other studies assessing global expression can be attributed to (i)
strict patient selection criteria, (ii) platform used to measure miRNA and gene expression,
and (iii) methods used for differential expression analysis.
Patients in this study strictly had early-onset disease, and by excluding a number of
maternal and fetal predisposing factors, the patients were better standardized as to the
pregnancy complications.8 Despite this current study being the largest to integrate
miRNA and gene expression data in these patient cohorts to our knowledge, a larger
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sample number or additional replication groups would be beneficial. However, strict
patient selection criteria were beneficial, and this is demonstrated in principal component
analyses based on miRNA and gene expression data in these patient groups that showed
clear segregation by disease status on the first principal component (Figure 2.1). In
addition, previous studies on PE do not always stratify patients into PE only and PE +
IUGR, whereas in our study, these two patient populations were segregated and treated as
distinct populations. Recent studies have shown distinct gene expression profiles for
different subclasses of PE (late vs. early, ± IUGR).38,39 Leavey et al. combined
microarray gene expression data from previously published studies in PE placentae, and
conducted unsupervised clustering analysis.39 The study identified three main subclasses
of PE based on gene expression - late-onset PE, which is mostly associated with term
deliveries and maternal risk factors (“maternal PE”); early-onset PE, which is likely
placental in origin and is more frequently associated with IUGR (“canonical PE”); and a
third subclass of PE that is also severe and can co-occur with IUGR but is likely due to
poor maternal-fetal compatibility (“immunologic PE”).39 Interestingly, cluster analysis
based on DNA methylation data in PE placentae revealed a similar clustering pattern into
the three subclasses of PE.40 In this study, 8763 and 340 differentially methylated sites
were found in the “canonical” and “immunologic” subclasses respectively.40 Wilson et al.
also showed differentially methylated sites, as many as 599 sites, in EO-PE and only 5 in
late-onset PE.41 These studies show differences in gene expression and in epigenetic
mechanisms between subclasses of PE, emphasizing that each subclass has a unique
underlying pathophysiology. In addition, these studies demonstrate the benefits of

51

combining epigenetic and gene expression data to improve our understanding of
molecular mechanisms in the placenta.
Next-generation sequencing used in this study to assess miRNA and gene expression has
many advantages compared to microarray platforms.42,43 The detection capacity of
microarrays is limited by the pre-determined probes on the array platforms, whereas NGS
data can be used to align to the most updated sequence information, which is beneficial
for the discovery of new miRNAs and genes. Moreover, NGS has a wider dynamic range
and is therefore capable of detecting miRNAs and mRNAs that are expressed at low
levels. Interestingly, from our miRNA study, we identified that our findings overlap more
with studies that have also used sequencing techniques compared to studies utilizing
microarray technology.34,44
Lastly, the stringency of statistical analyses to identify differentially expressed miRNAs
and genes is beneficial to increase confidence but could result in the exclusion of some
miRNAs and genes that may contribute to pathogenesis of PE and/or IUGR. On the other
hand, methods for analyzing high-throughput data are currently not standardized,
particularly normalization and identification of differences.45 Each program in this study
utilized a different approach to the normalization and differential expression analysis.
Therefore, using stringent cut-off values and including only miRNAs and genes identified
by two or more programs increased the reliability of our findings compared to using a
single approach for differential expression.
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2.5

Conclusion

In summary, this study shows that maldevelopment of the placenta early in gestation may
manifest itself into different complex diseases in the second and third trimester, however
some common underlying pathophysiological mechanisms remain in the placenta.
Identification of common miRNAs and genes that are dysregulated in all three patient
groups supports this observation. The gene expression data set allowed us to identify
potential novel gene targets that are primarily involved in cellular processes important for
placental growth and function. Identified candidate gene targets can be further
experimentally validated to demonstrate miRNA-mRNA interactions and to assess the
impact of miRNAs on gene expression. Identified miRNAs can also by assessed for their
efficacy as diagnostic biomarkers for these diseases. Continued integration of epigenetic
and gene expression data in larger disease cohort can validate findings and expand our
understating of molecular mechanisms impacting placental growth and function.
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2.7

Supplementary Information

Placenta obtained within 30 minutes of delivery
1 cm x 1 cm tissue sections dissected from two
central and two peripheral regions (4 samples)
Maternal (BPD) and fetal (CV) sides separated
by gross dissection and flash frozen in liquid
nitrogen
Maternal and fetal samples labelled and stored
separately at - 80°C until further analysis

Total RNA isolated only from the fetal side (CV)
from each of the four regions
Total RNA from the four regions is combined in
equal quantity to generate one RNA sample per
patient
MicroRNA
Sequencing

RNA Sequencing
(mRNA)

Figure 2.7 Journey of placental samples from delivery room to sequencing facility.
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Table 2.2 Criteria for selection of appropriate gene targets for microRNAs.
Two categories of criteria were used to identify potential gene targets for microRNAs in
each disease group. All microRNAs included in the final analysis meet all category 1
criteria and meet at least one of the category 2 criteria.
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Table 2.3 List of differentially expressed miRNAs in each disease group compared to
gestational age-matched controls (* BH adjusted p-value, + Effect Size).

Table 2.4 List of differentially expressed genes in each disease group compared to gestational age-matched controls (* BH adjusted pvalue, + Effect Size).
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Table 2.5 List of genes common between: PE Only and PE + IUGR, PE Only and IUGR
Only and PE + IUGR and IUGR Only.
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Table 2.6 Identified candidate gene targets based on inverse correlation analysis
including correlation coefficients and gene fold changes.
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Table 2.7 Global microRNA expression studies in human placenta from preeclamptic
patients.
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Chapter 3

3

The impact of microRNAs on gene target expression and
trophoblast cell functions

3.1 Introduction
MicroRNAs are endogenous, single stranded non-coding RNAs that regulate gene
expression post-transcriptionally via sequence complementarity that leads to mRNA
degradation or impaired translation.1,2 MiRNAs are transcribed in the nucleus and are
then processed in the cytoplasm into mature miRNAs of 20-22 nucleotides in length.1,2 In
the cytoplasm, miRNAs target messenger RNAs (mRNA) via perfect or imperfect base
pair complementarity to the 3´ untranslated region (3´UTR) of the mRNA.1-3 In
mammals, miRNAs are predicted to target approximately 60% of all protein-coding
genes.2,3 Studies have shown that miRNAs participate in the regulation of a wide
spectrum of cell processes including proliferation, apoptosis, differentiation and stress
response.2,3 MiRNAs are expressed highly in the placenta, and two placenta-specific
clusters have been identified on chromosomes 14 and 19.4,5 Studies have also identified
miRNA expression changes in placentae from pregnancy complications such as
preeclampsia (PE) and intrauterine growth restriction (IUGR).6,7 There is also evidence
that placental miRNAs can enter maternal circulation during pregnancy, sparking interest
in the utility of miRNAs as potential biomarkers for pregnancy associated diseases.8
PE is a maternal hypertensive disorder of pregnancy, affecting 2-8% of pregnancies
worldwide.9,10 The underlying pathophysiology of PE is not fully understood however,
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studies have shown that placental maldevelopment in early gestation may contribute to
the pathogenesis of PE.10,11 More specifically, the process of trophoblast cell migration
and invasion necessary to remodel maternal spiral arteries to accommodate for increased
uteroplacental blood flow is thought to be impaired.10,11 This can result in decreased
uteroplacental blood perfusion and subsequently a hypoxic intrauterine environment.10,11
A subset of patients with PE also develop IUGR, particularly early in gestation defined as
early-onset PE (< 34 weeks). IUGR is defined as poor fetal growth in utero, where
patients present with fetal weight lower than the 10th percentile estimated for gestational
age and gender, and can be associated with abnormal Dopplers in fetal and umbilical
vessels.12 PE and IUGR are pregnancy complications with common histopathological
features in the placenta.13,14 In addition, there is evidence to support that the intrauterine
environment in both PE and IUGR is relatively hypoxic.15 Hypoxia has been linked to the
upregulation of miR-210, and validated in vitro16,17 Increased expression levels of miR210 in placental and plasma samples from patients diagnosed with PE have been
consistently reported, and is one of the most commonly reported miRNAs in pregnancy
complications.18-20 Genes such as EFNA3 and HOXA9 have been validated as targets of
miR-210 in cell culture, and upregulation of miR-210 has been linked to impairment of
cell functions such as proliferation and migration of trophoblast cells in vitro. 17
We have previously identified miR-210-3p and -5p to be upregulated in placenta from PE
pregnancies irrespective of IUGR occurrence (Chapter 2). We have also identified the
upregulation of miR-193b-3p and -5p in placentae from pregnancies complicated with
early-onset PE only, IUGR only, and PE + IUGR compared to gestational age matched
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controls. In the same study, using RNA sequencing we assessed gene expression in the
same placental samples. Integration of the two datasets identified candidate gene targets
predominantly for miR-210-5p and miR-193b-5p. For miR-210-5p we identified 7
candidate gene targets in patients with early-onset PE + IUGR (APLN, C3AR1, CSF1,
ITGAM, SELE, TYRO3, VAV1), and 4 candidate gene targets in patients with early-onset
PE only (C3AR1, TYRO3, VAV1, WNT3). For miR-193b-5p, we identified 8 candidate
gene targets in patients with early-onset PE + IUGR (APLN, CSF1, FGF13, IL12RB2,
NRP2, PTGS1, TLR7, TYRO3), 5 candidate gene targets in patients with early-onset PE
only (CCR1, FGF13, IL12RB2, NTN4, TYRO3), and 1 candidate gene target in patients
with early-onset IUGR (FGF13).
The purpose of this study was to investigate the potential impact of miRNAs 210-5p and
193b-5p on identified gene targets and on trophoblast cell funtion in vitro. To fulfill this
purpose, the objectives were two-fold (i) examine whether miR-210-5p and miR-193b-5p
interact with candidate gene targets using luciferase assays in vitro, and (ii) if so,
overexpress miR-210-5p and miR-193b-5p in the extravillous trophoblast cell line HTR8/SVneo and assess the impact on target gene expression, migration, and proliferation of
cells.

3.2
3.2.1

Methods
Patient Recruitment

Preeclampsia was defined as hypertension (blood pressure > 140/90 mm Hg) and
proteinuria (³ 300 mg in 24 hours).9,10 Severe PE is often associated with HELLP
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syndrome characterized by the onset of: edema, headache, elevated liver enzymes, and
low platelet count. Patients diagnosed with PE and HELLP are indicated in Table 3.1.
Intrauterine growth restriction was defined as estimated fetal weight below the 10th
percentile for gestational age and gender, associated with abnormal umbilical and uterine
artery Dopplers.12 Patients with PE + IUGR presented with criteria aforementioned for
both diseases. Only patients diagnosed prior to 34 weeks (early-onset) were included in
this study. Patients with preterm labor and no other pregnancy complications before 34
weeks of gestation were recruited as controls. Women with diabetes, gestational diabetes,
pre-existing hypertension, obvious chorioamnionitis (status confirmed at delivery),
alcohol/drug use, chromosomal or genetic abnormalities, congenital anomalies, or
infection were excluded. All women enrolled in this study gave written informed consent
for the collection of samples and information. This research was approved by the office
of Human Research Ethics at Western University (REB # 102621).

3.2.2

Placental Tissue Sampling

Samples were collected from two central and two peripheral portions of the placenta
within 30 minutes of delivery. Central samples were collected within a 5 cm radius from
the umbilical cord insertion site and the peripheral samples were collected 2-3 cm from
the edge of the placenta. Full depth 1 cm x 1 cm tissue samples were excised, and the
maternal decidua was separated from the chorionic villi using gross dissection. In this
study, the maternal and fetal components were separated and only the fetal components
(chorionic villi) were used for analysis. The tissue samples were flash frozen in liquid
nitrogen and stored at -80°C until further analysis.
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3.2.3

Reverse Transcription and Real-Time PCR (Placenta Tissue)

Total RNA was isolated from 80-100 mg of tissue samples from each of the four regions
of each placenta using the mirVana RNA isolation kit (Life Technologies, Waltham, MA,
USA). Sample quantity and quality was checked using the Agilent Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA, USA). Total RNA isolated from central and
peripheral samples of each placenta was pooled in equal quantities for one representative
total RNA sample from each patient. Total RNA was reversed transcribed using the High
Capacity cDNA Synthesis Kit (Life Technologies™, Waltham, MA, USA). Quantification
for mRNAs was completed using the TaqMan® fast advanced PCR master mix (Life
Technologies, Waltham, MA, USA) in conjunction with TaqMan gene expression assays.
GAPDH was used as an endogenous control. All samples were assayed in triplicate and
run on the ViiA7™ real-time machine. The 2-ΔΔCt method was used for fold-change
analysis.

Mann-Whitney

(Hs00175572_m1),

U

C3AR1

test

was

used

(Hs00269693_s1),

for

statistical

CCR1

analysis.

(Hs00928897_s1),

APLN
CSF1

(Hs00174164_m1), FGF13 (Hs00182807_m1), IL12RB2 (Hs00155486_m1), ITGAM
(Hs00167304_m1), NRP2 (Hs00187290_m1), NTN4 (Hs00221915_m1), PTGS1
(Hs00377726_m1),

SELE

(Hs00950409_g1),

TLR7

(Hs01933259_s1),

TYRO3

(Hs03986773_m1), VAV1 (Hs01041613_m1), WNT3 (Hs00902257_m1).

3.2.4

Target Prediction

A combination of target prediction tools were used to predict targets, software tools
include: TargetScan Human (http://www.targetscan.org/vert_70), Diana micro-T CDS
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(http://diana.imis.athena-innovation.gr/DianaTools/),

miRwalk

heidelberg.de/apps/zmf/mirwalk2),

(http://mirdb.org),

miRDB

(http://zmf.umm.unimiRanda

(http://microrna.sanger.ac.uk/targets), and PicTar (https://pictar.mdc-berlin.de).

3.2.5

Luciferase Assays

HTR-8/SVneo cells were cultured in RPMI-1640 media (Gibco, California, USA)
supplemented with 10% fetal bovine serum in a 37°C humidified incubator (5% CO2).
Cells were subcultured at a ratio of 1:3 when cells reached 80% confluency. Plasmids
containing the firefly luciferase gene and the 3´UTRs of candidate genes APLN
(S813689), CSF1(S807015), FGF13 (S808593), ITGAM(S808425), TYRO3 (S808004),
C3AR1 (S803358) were obtained from Active Motif (Carlsbad, CA, USA).
DharmaFECT Duo transfection reagent (GE Healthcare, Boston, MA, USA) was used to
co-transfect the firefly plasmid (100 ng) with hsa-miR-210-5p mimics, or hsa-miR-193b5p mimics or NC mimics, 100 nM each. Control 3´UTR reporter vectors were also used,
empty 3´UTR (100 ng) (S890005) and 3´UTR of GAPDH (100 ng) (S801378). After 24hour incubation, luciferase activity was measured using the LightSwitch™ Luciferase
assay reagent (Active Motif, Carlsbad, CA, USA).

3.2.6

Immunohistochemistry

Whole sections (0.5 cm x 0.5 cm) were harvested from the placenta, extending from the
basal plate decidua into the chorionic villus (maternal and fetal sides). Both central (near
umbilical cord insertion site) and peripheral (near outer edge of the tissue) sections were
collected. The specimens were immediately fixed in 10% formalin for a minimum of 24
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hours. Following fixation and washing, tissues were processed, and paraffin embedded.
All tissues were then serially sectioned at a thickness of 5 μm using a microtome and
mounted onto slides. Slides were then deparaffinized and rehydrated, and antigen
retrieval was performed in citrate buffer (pH 6.0). For APLN and FGF13, the antigen
retrieval step was not performed. Slides were then blocked with a blocking agent,
Background Sniper (BS966, Biocare Medical, Pacheco, CA, USA). The primary antibody
was then applied for: APLN (1:15) (ab181786, Abcam), FGF13 (1:1000) (ab153808,
Abcam), CSF1 (1:75) (ab52864, Abcam), and ITGAM (1:75) (ab52478, Abcam). Slides
were incubated with the primary antibody overnight. The slides were then rinsed and the
secondary antibody, ImmPRESS Anti-Rabbit Peroxidase Polymer Detection Kit (MP7401, Vector Laboratories, Burlington, ON, Canada), was applied. The slides were rinsed
again and labeled with a DAB (3,3′–diaminobenzidine) stain (1718096001, St. Louis,
MO, USA). Negative control slides underwent the same procedures, with the exception
of the application of the primary antibody. Finally, a CAT Hematoxylin (CATHE,
Biocare Medical, Pacheco, CA, USA) counterstain was applied to all slides. Imaging was
performed using a 200 x total magnification on a Zeiss AxioImager Z1 Microscope using
Zen software and an MRc5 camera (Zeiss Canada Ltd., North York, ON).

3.2.7

Cell Culture and Treatment

HTR-8/SVneo cells were cultured in RPMI-1640 media (Gibco, California, USA) with
10% fetal bovine serum in a 24-well plate, at 37°C in 5% CO2. Cells were subsequently
transfected using DharmaFECT 1 transfection reagent (GE Healthcare, Boston, MA,
USA). For miR-210-5p experiments cells were transfected with: 50 nM of miR-210-5p
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mimics (MC27291), or 100 nM of miR-210-5p inhibitors (MH27291), or respective
negative control (NC) mimics (50 nM, 4464058), NC inhibitors (100 nM, 4464076)
(ThermoFisher, Waltham, MA, USA). For miR-193b-5p experiments cells were
transfected with: 50 nM of miR-193b-5p mimics (MIM0232), 100 nM of miR-193b-5p
inhibitors (INH0232), or respective NC mimics (50 nM, MIM9001), NC inhibitors (100
nM, INH9001) (Active Motif, Carlsbad, CA, USA). After transfection, cells were lysed
for gene or protein expression analysis or used to measure cell functions.

3.2.8

Reverse Transcription and Real-time PCR (Cells)

HTR-8/SVneo cells were seeded and transfected as described previously. Total RNA was
isolated from HTR-8/SVneo cells using Qiagen’s RNeasy Mini kit (74104, Qiagen,
Germany). Cells were lysed using lysis buffer provided in the kit and further
homogenized by passing lysate through a 20-gauge needle. Total RNA is then used for
reverse transcription and real-time PCR as described above in Methods section 3.2.3.

3.2.9

Western Blotting

HTR-8/SVneo cells were seeded and transfected as described previously. Cells were then
lysed using RIPA buffer containing protease and phosphatase inhibitors (Sigma-Aldrich,
St. Louis, MO, USA). Bradford assay was used to assess protein concentration. Lysates
were then resolved on SDS-PAGE and transferred to a PDVF membrane using the BioRad Trans-Blot Turbo transfer system (Bio-Rad, Hercules, CA, USA). Membranes were
incubated with primary antibodies against APLN (1:200) (sc-293441, SantaCruz
Biotechnology), FGF13 (1:500) (ab153808, Abcam), CSF1 (1:500) (sc-365779,
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SantaCruz Biotechnology), ITGAM (1:500) (sc-515923, SantaCruz Biotechnology,
ab52478, Abcam) or beta-actin (MS1295P, ThermoFisher) at 4°C overnight. Following
this, membranes were washed and incubated with horse radish peroxidase (HRP)
conjugated secondary antibody (170-6516, Bio-Rad, Hercules, CA, USA). Resolved
protein bands were detected using chemiluminescence, and images were taken using the
VersaDoc Imaging System (Bio-Rad, Hercules, CA, USA).

3.2.10

Cell Viability Assay

HTR-8/SVneo cells were seeded and transfected as described previously. Cell
proliferation was measured using cell proliferation reagent WST-1 (Sigma-Aldrich, St.
Louis, MO, USA) according manufacturer’s protocol. After 1 hour incubation with the
WST-1 reagent, absorbance was measured at 450 nm using Multiskan Ascent plate
reader (ThermoFisher, Waltham, MA, USA). Reference wavelength of 650 nm was used,
and culture medium was used as a blank.

3.2.11

Wound Healing (scratch) Assay

An in vitro scratch assay was used as described previously. 21 After transfection, HTR8/SVneo cells were grown to confluence, and scratches were made using a p200 pipette
tip. The width of the scratch was monitored by Leica DM IL microscope, images were
taken at 0 hours and 24 hours using 40 x total magnification. Width of the scratch was
then measured using Image J Software, distance travelled is shown as migration level
relative to control samples.
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3.2.12

Transwell Migration Assay

Transwell compartments were prepared in a 24-well plate format, with BD Falcon™ 8.0µm pore Transwell cell culture inserts (353097; BD Biosciences, Franklin lakes, NJ,
USA). For the lower compartment 0.8 mL of RPMI-1640 media with 10% FBS was
added. For the upper compartment, 1 x 105 transfected cells in 0.2 mL serum-free RPMI1640 media were gently added. After 24 hours incubation at 37°C and 5% CO2 nonmigrated cells on the top surface of membrane were carefully removed. Migrated cells on
the bottom surface of the membrane were fixed with methanol and stained with 0.2%
crystal violet. Inserts were imaged using Leica DM IL inverted microscope and 200 x
total magnification. Number of cells counted is shown as migration level relative to
control samples.

3.2.13

Statistical Analyses

GraphPad Prism Software 6.0 was used to generate all graphs and analyses. Statistical
analysis was performed using the Mann-Whitney U-test or a two-tailed Student’s t-test, a
threshold of p-value < 0.05 was considered significant. Graphic representation values are
presented as mean ± SEM. For correlation analysis, Pearson correlation co-efficient was
used for graphical representation of correlation analysis between miRNA and gene
expression values. Only correlation with a r of £ -0.5 and adjusted p-value £ 0.01 was
considered significantly negatively correlated. All experiments were repeated three times
independently.
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3.3
3.3.1

Results
Clinical Information

Clinical characteristics of the patient populations are shown in Table 3.1. There were no
differences in maternal age, BMI or gestational age at delivery between patient groups.
Each patient group has an equal number of male and female outcome pregnancies. There
were significant differences in birth, placental weights and blood pressure between
patient groups with complicated pregnancies and gestational age-matched controls. Birth
and placental weights were also significantly lower in the PE + IUGR group compared to
the PE only and IUGR only groups. These patient populations were the same populations
used for the sequencing expression study (Chapter 2). These patients were selected using
stringent inclusion and exclusion criteria to include patients with primarily placental
factors underlying the diseases. Patients with known maternal and/or fetal risk factors
were not included (see methods).
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Table 3.1 Clinical characteristics of the patient groups with complicated pregnancies and
gestational age-matched controls.

1) p-value < 0.05 vs. control 2) p-value < 0.001 vs. control 3) p-value <0.0001 vs. control 4) p-value <0.01
vs. PE only 5) p-value < 0.0001 vs. IUGR only
Note: Table 3.1 is identical to Table 2.1, the table is provided in this chapter for ease of reference.
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3.3.2

Real-time PCR confirmation of candidate genes targets

In our previous study assessing global miRNA expression using NGS in placentae from
patients diagnosed with early-onset complications, we identified upregulation of miR210-5p and miR-193b-5p. miR-210-5p was upregulated in two patient groups (PE, PE
+IUGR) , and miR-193b-5p was upregulated in all three patient groups (PE, IUGR, PE
+IUGR) compared to gestational age matched controls. These findings were also
confirmed using qRT-PCR. Integration of miRNA and gene expression data identified a
subset of predicted targets, and the majority of candidate genes were targets for miR193b-5p and miR-210-5p. Here we confirmed differential downregulation of candidate
gene targets for miR-210-5p and miR-193b-5p using qRT-PCR.
Figure 3.1 shows qRT-PCR results for miR-210-5p candidate gene targets in the PE only
group, PE + IUGR, or both. All candidate gene targets confirmed downregulation of
expression, with the exception of VAV1 and WNT3 in the PE only group (Figure 3.1).
Figure 3.2 shows qRT-PCR results for miR-193b-5p candidate gene targets. The majority
of identified genes are downregulated in the PE + IUGR group (Figure 3.2b). FGF13 is
the only candidate gene target that is down-regulated in all 3 patient groups (Figure 3.2a).
All candidate gene targets were confirmed to be downregulated in their respective patient
group, with the exception of CCR1 and NTN4 in the PE only group (Figure 3.2).
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Figure 3.1 mRNA expression levels of candidate gene targets for miR-210-5p
To find relative mRNA expression of candidate gene targets the DDCT method was used
and values were normalized to GAPDH expression. All samples were run in triplicate.
Data is shown as the mean ± SEM, significant differences were determined using a
Mann-Whitney U test. * p-value <0.05
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Figure 3.2 mRNA expression levels of candidate gene targets for miR-193b-5p
To find relative mRNA expression of candidate gene targets the DDCT method was used
and values were normalized to GAPDH expression. A. Candidate targets identified
primarily in more than one patient group. B. Candidate targets identified only in patients
with PE + IUGR. All samples were run in triplicate. Data is shown as the mean ± SEM,
significant differences were determined using Mann-Whitney U test. ** p-value <0.01
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3.3.3

Validating candidate gene targets

To confirm the interaction between miRNAs and candidate gene targets, a human
trophoblast cell line, HTR-8/SVneo was used for luciferase assays. HTR-8/SVneo cells
were co-transfected with plasmids containing the firefly luciferase and the 3´UTR of the
target gene of interest, along with miRNA mimics or NC mimics. Plasmids containing
the firefly luciferase along with the GAPDH 3´UTR or an empty 3´UTR were used as
controls.
3.3.3.1 miR-210-5p targets
Based on qRT-PCR results VAV1 and WNT3 were not selected for validation using
luciferase assays. We conducted luciferase assays for C3AR1, CSF1, ITGAM and TYRO3.
Significant decrease in relative luciferase activity was observed in HTR-8/SVneo cells
containing 3´UTRs of either CSF1 or ITGAM (Figure 3.3a). However, no changes were
observed in cells containing the 3´UTRs of C3AR1 or TYRO3 (data not shown). Both
CSF1 and ITGAM were predicted targets by more than one software prediction tool at the
same nucleotide positions, including TargetScan and miRanda. miR-210-5p is predicted
to target CSF1 at 2380-2387 nt region of the 3´UTR, and ITGAM at the 3887-3894 nt
region of the 3´UTR (Figure 3.3 b). Inverse correlation analysis using sequencing data
had previously shown significant negative inverse correlation between the expression of
miR-210-5p and CSF1 (r = - 0.81), and between miR-210-5p and ITGAM (r = - 0.80) in
the control and PE + IUGR groups (Figure 3.3 c, d).
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Figure 3.3 Validation of miR-210-5p candidate gene targets
A. Relative luciferase activity measured 24 hours after co-transfection of HTR-8/SVneo
cells with luciferase constructs containing 3´UTR of CSF1, or ITGAM, or control
constructs, along with miR-210-5p mimic or NC mimic. Data is shown as mean ± SEM;
** indicates p-value < 0.01 B. Schematic of the luciferase construct and sequence
alignment between miR-210-5p and gene targets. Significant negative correlation
between the expression values of C. miR-210-5p and CSF1 and D. miR-210-5p and
ITGAM obtained from miRNA and RNA-seq expression datasets in patients with PE +
IUGR and gestational age-matched controls.
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3.3.3.2 miR-193b-5p targets
Based on qRT-PCR results, CCR1 and NTN4 were not selected for validation using
luciferase assays. Based on assay availability and prior knowledge of candidate gene
targets, we prioritized conducting luciferase assays for APLN, CSF1, FGF13 and TYRO3.
Significant decrease in relative luciferase activity was observed in HTR-8/SVneo cells
containing 3´UTRs of either APLN or FGF13 (Figure 3.4a). However, no changes were
observed in cells containing the 3´UTRs of CSF1 or TYRO3 (data not shown). APLN and
FGF13 were predicted targets by more than one software prediction tool at the same
nucleotide positions. miR-193b-5p is predicted to target APLN at 1243-1249 nt region of
the 3´UTR, and FGF13 at the 741-747 nt region of the 3´UTR (Figure 3.4 b). Inverse
correlation analysis using sequencing data had previously shown significant negative
inverse correlation between the expression of miR-193b-5p and APLN (r = - 0.82), and
between miR-193b-5p and FGF13 (r = - 0.82) in the control and PE + IUGR groups
(Figure 3.4 c,d). Since FGF13 is down-regulated in the PE only and the IUGR only
groups, there is also significant inverse correlation between the expression of miR-193b5p and FGF13 in these groups (r = -0.82 and -0.77 respectively) (Figure 3.4 e,f).
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Figure 3.4 Validation of miR-193b-5p candidate gene targets
A. Relative luciferase activity measured 24 hours after co-transfection of HTR-8/SVneo
cells with luciferase constructs containing 3´UTR of APLN, or FGF13, or control
constructs, along with miR-193b-5p mimic or NC mimic. Data is shown as mean ± SEM;
*** indicates p-value < 0.001 B. Schematic of the luciferase construct and sequence
alignment between miR-193b-5p and gene targets. Significant negative correlation
between the expression values of C. miR-193b-5p and APLN in the PE + IUGR group,
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and miR-193b-5p and FGF13 in the D. PE + IUGR group, E. PE only group, and F.
IUGR only group obtained from miRNA and RNA-seq expression datasets.

3.3.4

Immunohistochemical analysis of gene targets in the placenta

Immunohistochemical analysis of the placenta was conducted to identify which cell types
most prominently express gene targets. Staining was completed in PE + IUGR samples
(N=2) and gestational-age matched preterm control samples (N=2) for localization of
each gene target in both patient groups. For each sample both CV and BPD were stained
from whole sections obtained from central and peripheral regions of the placenta. Each
gene target evaluated localized to the same cell types in control and PE +IUGR samples.
CSF1 strongly localized to Hofbauer cells in tertiary chorionic villi, meanwhile lighter
staining was observed in the CT and SCT cells (Figure 3.5). ITGAM localized to SCT
cells in tertiary villi, and both ITGAM and CSF1 were expressed in intermediate CT cells
within the basal plate decidua (Figure 3.5). APLN and FGF13 strongly localized to SCT
cells, whereas APLN also localized to CT cells and the chorionic villus stroma (Figure
3.6). In the BPD, APLN and FGF13 localized to intermediate CT cells (Figure 3.6).
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Figure 3.5 Immunohistochemical staining for gene targets CSF1 and ITGAM
Staining for CSF1 in preterm control placenta (A,B) and in early-onset PE + IUGR
(C,D), gestational age 29+4 and 29+6 respectively. Staining for ITGAM in preterm
control placenta (E,F) and in early-onset PE + IUGR (G,H), gestational age 31+5 and
32+1 respectively. Black arrows show positivity in SCT cells, white arrows show
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positivity in CT cells, red arrows show positivity in Hofbauer cells, green arrows show
positivity in intermediate CT cells. All images were captured at 200 x total magnification.

Figure 3.6 Immunohistochemical staining for gene targets APLN and FGF13
Staining for APLN in preterm control placenta (A,B) and in early-onset PE + IUGR
(C,D), gestational age 29+4 and 29+6 respectively. Staining for FGF13 in preterm
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control placenta (E,F) and in early-onset PE + IUGR (G,H), gestational age 31+5 and
32+1 respectively. Black arrows show positivity in SCT cell, white arrows show
positivity in CT cells, green arrows show positivity in intermediate CT cells. All images
were captured at 20 x.

3.3.5

Expression levels of candidate gene targets in HTR-8/SVneo cells

3.3.5.1 miR-210-5p
HTR-8/SVneo cells were transfected with either miR-210-5p mimics or inhibitors.
Following treatment, mRNA and protein expression levels of CSF1 and ITGAM were
measured in these cells and compared to cells transfected with NC mimics or NC
inhibitors. Transfection of miR-210-5p mimics into HTR-8/SVneo cells resulted in a
decrease in CSF1 and ITGAM mRNA expression (Figure 3.7 a,b). Conversely,
transfection of miR-210-5p inhibitors into HTR-8/SVneo cells increased CSF1 and
ITGAM mRNA expression (Figure 3.7 a, b). Similar trends in expression were observed
for CSF1 protein after transfection (Figure 3.7 c, d). ITGAM protein in HTR-8/SVneo
cells was undetectable using two different commercially available antibodies, although
detectable in placental tissues using the same antibodies (data not shown). ITGAM
protein was also undetectable in BeWo cells, another trophoblast cell line (data not
shown).
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Figure 3.7 Impact of miR-210-5p on target gene expression
A. CSF1 and B. ITGAM mRNA expression in HTR-8/SVneo cells transfected with miR210-5p mimics or inhibitors and compared to the corresponding control (NC mimic or
inhibitor) as detected by qRT-PCR and normalized to GAPDH expression using the
DDCT method. C. Western blot analysis showed CSF1 protein levels in HTR-8/SVneo
cells following transfection with miR-210-5p mimics (top panel) or inhibitors (lower
panel) and compared to the corresponding control (NC mimic or inhibitor) D. Summary
graph from three independent experiments, CSF1 density was normalized to b-actin in
the same blot. Values represent mean ± SEM; ** indicates p-value < 0.01
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3.3.5.2 miR-193b-5p
HTR-8/SVneo cells were also transfected with either miR-193b-5p mimics or inhibitors.
Following treatment, mRNA and protein expression levels of APLN and FGF13 were
measured in these cells and compared to cells transfected with NC mimics or NC
inhibitors. Transfection of miR-193b-5p mimics into HTR-8/SVneo cells resulted in a
decrease in APLN and FGF13 mRNA expression (Figure 3.8 a,b). Meanwhile
transfection of miR-193-5p inhibitors into HTR-8/SVneo cells increased APLN and
FGF13 mRNA expression (Figure 3.8 a, b). No changes were observed in APLN or
FGF13 protein levels after transfection with miR-193b-5p mimics or inhibitors (Figure
3.8 c,d).
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Figure 3.8 Impact of miR-193b-5p on target gene expression
A. APLN and B. FGF13 mRNA expression in HTR-8/SVneo cells transfected with miR193b-5p mimics or inhibitors and compared to the corresponding control (NC mimic or
inhibitor) as detected by qRT-PCR and normalized to GAPDH expression using the
DDCT method. Western blot analysis to show C. APLN and D. FGF13 protein levels in
HTR-8/SVneo cells following transfection with miR-193b-5p mimics (top panel) or
inhibitors (lower panel) and compared to the corresponding control (NC mimic or
inhibitor). Protein density was normalized to b-actin in the same blot. Values represent
mean ± SEM; * indicates p-value < 0.05
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3.3.6

Impact on trophoblast proliferation and migration

To investigate the impact of miRNAs on cell functions, HTR-8/SVneo cells were
transfected with miRNA mimics, inhibitors, or corresponding controls and cell
proliferation and migration were assessed. Cell proliferation was measured with a WST-1
reagent following transfections. Cell migration was measured using a wound healing
assay and a transwell assay.
3.3.6.1 miR-210-5p
Transfection of HTR-8/SVneo with miR-210-5p mimics decreased proliferation and
migration of cells. The fraction of viable cells was 20% less in cells treated with miR210-5p mimics compared to cells treated with NC mimics. Meanwhile the wound healing
assay showed a 30% decrease in relative migration levels, and the transwell assay showed
a 60% reduction. Transfection of HTR-8/SVneo with miR-210-5p inhibitors had no
impact on proliferation but promoted migration of cells (Figure 3.9). After treatment with
miR-210-5p inhibitors the wound healing assay showed a 35% increase in relative
migration levels, meanwhile the transwell assay showed a 65% increase.
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Figure 3.9 miR-210-5p impact on cell functions in human trophoblast cells
A. Effect of miR-210-5p on cell proliferation was investigated using WST-1 reagent.
Cells were incubated with WST-1 reagent following transfection with miR-210-5p mimic
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or inhibitor and compared to the corresponding control (NC mimic or inhibitor). B. To
investigate the effect of miR-210-5p overexpression and inhibition on cell migration,
HTR-8/SVneo cells were transfected with miR-210-5p mimics, inhibitor, or the
corresponding control, scratches were then created and the width of the scratch in each
experimental group was measured at time 0 and at 24 hours using 40 x total
magnification. Migration level is the distance traveled in 24 hours relative to the control
group. C. Transfected HTR-8/SVneo cells were transferred into a transwell chamber to
assess impact on migration; images were taken 24 hours after seeding using 200 x total
magnification. Migration level is the number of cells migrated through the membrane
relative to the control group. All experiments were repeated three times independently,
data is shown as mean ± SEM ** indicates P < 0.01
3.3.6.2 miR-193b-5p
Transfection of HTR-8/SVneo cells with miR-193b-5p mimics decreased proliferation
and migration of cells (Figure 3.10). The fraction of viable cells was 25% less in cells
treated with miR-193b-5p mimics compared to cells treated with NC mimics (Figure
3.10a). On the other hand, the wound healing assay showed a 35% decrease in relative
migration levels, and the transwell assay showed a 50% reduction (Figure 3.10 b, c).
Transfection of HTR-8/SVneo with miR-193b-5p inhibitors had no impact on
proliferation but promoted migration of cells (Figure 3.10). After treatment with miR193b-5p inhibitors the wound healing assay showed a 25% increase in relative migration
levels, meanwhile the transwell assay showed a 45% increase (Figure 3.10 b, c).
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Figure 3.10 miR-193b-5p impact on cell functions in human trophoblast cells
A. Effect of miR-193b-5p on cell proliferation was investigated using WST-1 reagent.
Cells were incubated with WST-1 reagent following transfection with miR-193b-5p
mimic or inhibitor and compared to the corresponding control (NC mimic or inhibitor).
B. To investigate the effect of miR-193b-5p overexpression and inhibition on cell
migration, HTR-8/SVneo cells were transfected with miR-193b-5p mimics or inhibitor,
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or the corresponding control, scratches were then created and the width of the scratch in
each experimental group was measured at time 0 and at 24 hours using 40 x total
magnification. Migration level is the distance traveled in 24 hours relative to the control
group. C. Transfected HTR-8/SVneo cells were transferred into a transwell chamber to
assess impact on migration, images were taken 24 hours after seeding using 200 x total
magnification. Migration level is the number of cells migrated through the membrane
relative to the control group. All experiments were repeated three times independently,
data is shown as mean ± SEM ** indicates P < 0.01

3.4
3.4.1

Discussion
MicroRNAs

In our previous study investigating miRNA expression in placenta from patients
diagnosed with early-onset pregnancy complications, we identified significant
upregulation of miR-210-5p in patients with PE (± IUGR) and miR-193b-5p in all three
pregnancy complicated patient groups (PE only, IUGR only, PE +IUGR). Gene
expression data from the same patients allowed us to identify predicted gene targets for
differentially expressed miRNAs. A significant number of predicted genes identified
were targets for miR-210-5p and/or miR-193b-5p, therefore these two miRNAs became
of primary interest.
3.4.1.1 miR-210
miR-210 is one of the most widely identified miRNAs in placentae from complicated
pregnancies, it is identified to be upregulated in placenta from patients with PE only, and
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patients with PE and SGA babies.18,22,23 In the human placenta, using in situ
hybridization, miR-210 expression has been localized to the villous trophoblast and the
extravillous interstitial trophoblast.22 In addition, miR-210 has been widely investigated
for its potential use as a diagnostic biomarker, both miR-210-3p and miR-210-5p
expression levels were found to be significantly higher in maternal plasma from PE
patients.19,20
As previously mentioned, the intrauterine environment in pregnancies complicated by PE
and/or IUGR can be hypoxic due to decreased perfusion of maternal blood into the
uteroplacental unit.15 It is now known that under hypoxic conditions, miR-210 is
upregulated in expression, and upregulation is mediated by the transcription factors HIF1a or NF-κB.16,17 Isolated trophoblast cells from first trimester placenta cultured under
hypoxic conditions, show significant increases in miR-210 expression.17 To assess the
impact of miR-210 upregulation in PE placenta, studies identified gene targets that are
downregulated and are implicated in processes important for placental function.17,22 Gene
targets validated using cell culture methods include: EFNA3, HOXA1, ISCU, KCMF1,
and THSD7A.17,22,24,25 Validated gene targets implicate miR-210 in important functions
such as cell migration, invasion, growth/proliferation, and mitochondrial metabolism.17,2427

Based on evidence implicating miR-210-3p in important trophoblast cell functions 24-27

we sought to assess the impact of miR-210-5p on HTR-8/SVneo cell proliferation and
migration. Transfection of cells with miR-210-5p mimics reduced proliferation and
migration of cells, while inhibition of miR-210-5p only had an effect on cell migration
(Figure 3.9).
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3.4.1.2 MiR-193b-5p
Previous reports assessing placental miRNA expression in PE pregnancies identified an
upregulation in miR-193b-3p and -5p.28-31 Previous reports including those that utilized
high throughput sequencing identified miR-193b-3p and -5p, including our own
study.29,31 Meanwhile studies using array-based technology only identified miR-193b-3p
to be upregulated.28,30,32 To investigate whether miR-193b-5p had impact on cell
functions similar to its complementary strand miR-193b-3p, we measured cell
proliferation and migration. miR-193b-3p has been shown to target TGFβ2 in trophoblast
cell culture, where the increase in miR-193b-3p expression reduced TGFβ2 expression
and reduced the cell’s capacity for migration and invasion.31 In cancer cells, miR-193b3p is shown to regulate cell proliferation, migration, and invasion.33,34 Meanwhile, miR193b-5p has only been shown to impact cell proliferation in cancer cells.35 In this study,
miR-193b-5p upregulation had pronounced impact on cell migration, shown using a
wound healing and transwell assays, and only a modest but significant decrease in cell
proliferation (Figure 3.10). Inhibition of miR-193b-5p only had significant effects on cell
migration (Figure 3.10).

3.4.2

Trophoblast Cells

To better understand the function and development of trophoblast cells in the placenta, a
number of trophoblast cell lines have been created in vitro. Freshly isolated CT cells from
the placenta can also be used, however these cells do not proliferate in culture and have a
short life span in vitro (maximum 7 days) where they also fuse to form syncytia.36,37 The
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short life span of freshly isolated CT cells makes molecular manipulation of these cells
difficult, therefore immortalized trophoblast cell lines have been created to study
trophoblast biology and function.36,37 As previously mentioned, trophoblast cells in the
placenta differentiate into the VT and EVT pathways.38 Villous CT cells are responsible
for the growth and expansion of the placental exchange site, they fuse to form SCT cells
which cover the villi, and are important for hormone production, and gas, nutrient and
waste exchange.38 Extravillous CT cells on the other hand, adopt migratory and invasive
properties required to invade the maternal myometrium and remodel spiral arteries
properly to accommodate for increased demand of blood supply.38 Based on the working
hypothesis that EVT cell dysfunction and improper spiral artery remodeling are potential
underlying causes for pregnancy complications such as PE and IUGR, there was and still
is strong emphasis on creating in vitro systems to study EVT cell properties, particularly
how epithelial-to-mesenchymal transition is regulated.39,40 The mostly commonly used
immortalized trophoblast cell line to study EVT cell function is the HTR-8/SVneo cell
line. This cell line was created by Graham et al. in 1993 by isolating EVT cells from first
trimester villous explants from terminated pregnancies, called HTR-8.41 HTR-8 cells
were then immortalized by transfecting the gene encoding the simian virus 40 (SV40)
large T antigen using electroporation, creating the HTR-8/SVneo cell line.41
Based on immunohistochemical analysis in our placental tissues, we identified expression
of gene targets in placental trophoblast cells. More specifically, all four gene targets
showed strong reactivity in intermediate cytotrophoblast cells (Figure 3.5 and 3.6). In
addition, gene expression analysis for gene targets in unmanipulated HTR-8/SVneo cells
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revealed abundant mRNA and protein expression for all gene targets, with the exception
of ITGAM protein. Previous literature evidence implicates miRNAs in important CT cell
functions important for the EVT pathway including proliferation, migration and
invasion.42-44 Finally, global miRNA expression in HTR-8/SVneo cells showed wide
expression of miRNAs including placenta-specific miRNAs.45
For the study of VT biology, naturally occurring immortalized trophoblast cells from
choriocarcinomas are more commonly used. Examples of these cell lines include: BeWo,
JEG-3 and JAR.39,40 Addition of bromo-cAMP to BeWo cell culture triggers fusion and
syncytialization of cells.46 Therefore, the BeWo cell line is commonly used to investigate
processes of involving transcellular transport and syncytialization.46

3.4.3

Gene Targets

Target prediction tools identified a number of candidate gene targets for miR-210-5p and
miR-193b-5p. Luciferase assays were used to test for miRNA : mRNA interactions, and
transfection of HTR-8/SVneo cells with miRNA mimics and a luciferase plasmid
containing the 3´UTR of the target of interest identified CSF1 and ITGAM as primary
targets for miR-210-5p, and APLN and FGF13 as primary targets for miR-193b-5p
(Figures 3.3 and 3.4).
Transfection of HTR-8/SVneo with miRNA mimics and inhibitors impacted gene target
expression. In cells transfected with miR-210-5p mimics, CSF1 and ITGAM mRNA
expression was decreased, whereas protein levels of only CSF1 were decreased (Figure
3.7). ITGAM protein was not detectable in HTR-8/SVneo cells although strongly

112

expressed in chorionic villi homogenates. Therefore, it is possible that ITGAM mRNA
translation into a full functional protein may be dependent upon the environment.
Culturing trophoblast cells in the presence of other placental cell types such as
endothelial cells may trigger mRNA translation into protein.
Transfection of HTR-8/SVneo cells with miR-193b-5p mimics decreased APLN and
FGF13 mRNA expression, miR-193b-5p inhibitors increased APLN and FGF13 mRNA
expression (Figure 3.8). However, changes in mRNA levels were not reflected in protein
levels of APLN and FGF13 with either treatment (Figure 3.8). This can potentially be
attributed to (i) presence of multiple transcripts for the same gene, (ii) post-transcriptional
modifications, or (iii) limitation of using western blotting as a detection method to
measure protein levels.
3.4.3.1 CSF1
In our search for targets, it was interesting to note that CSF1 receptor (CSF1R) was also a
predicted target of miR-210-5p. Colony-stimulating factor-1 is a growth factor that is
known to regulate proliferation, migration, and differentiation of mononuclear
phagocytes, through a transmembrane tyrosine kinase receptor, CSF1R.47 Expression of
CSF1

and

its

receptor

CSF1R

has

been

detected

in

the

placenta.48-51

Immunohistochemical staining shows widespread CSF1R expression in placental
trophoblast in first trimester placenta, meanwhile CSF1 expression was detected in the
CT lining the villous core.50 In placenta from early- and late-onset PE compared to term
controls CSF1 was localized to CT and SCT cells, however when quantified no
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differences were found between groups.51 In placental samples from our patient groups
CSF1 is localized to SCT and CT layers but is primarily expressed in Hofbauer cells in
the CV, and in intermediate CT cells shown in the BPD (Figure 3.5 a-d).
EVT cells propagated in cell culture continue to express CSF1 and CSF1R mRNA and
protein, and addition of exogenous CSF1 to EVT cell cultures significantly stimulated
proliferation but had no impact on cell invasiveness.52 Another study suggested a role for
CSF1 in trophoblast cell proliferation and showed CSF1 could be acting in part through
HLX1 to regulate cell proliferation.53 In addition, treatment of term placental CTs with
exogenous CSF1 in culture, increases the number and size of multinucleated structures
forming extended stretches of syncytium, thereby implicating CSF1 in syncytialization of
trophoblast cells.54,55 There is evidence to support that CSF1 can be regulated by
miRNAs and is shown in ovarian cancer cells, where CSF1 is a target for miR-128 and
miR-152, and overexpression of miRNAs correlated with a decrease in CSF1 expression
impacting cell migration and adhesion.56
Reports on the expression of macrophage-CSF (M-CSF) and granulocyte-macrophageCSF (GM-CSF) in blood and placenta from PE pregnancies are conflicting.51, 57-59 While
some studies report an increase in M-CSF levels in the maternal sera and an increase in
GM/M-CSF in the placenta, others report no change.51,57-59 Meanwhile a study in patients
diagnosed with IUGR, found M-CSF levels to be significantly lower in amniotic fluid
samples.60 Conflicting reports can be attributed to lack of standardization of the patient
selection process, for example grouping early- and late-onset PE patients together or
grouping patients with PE ± IUGR together.
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3.4.3.2 ITGAM
Integrin subunit alpha M, also known as ITGAM or CD11b, binds non-covalently to a β2
subunit (CD18) to form integrin ⍺Mβ2, that is expressed in monocytes, granulocytes, and
macrophages.61,62 CD11b/CD18 have the capacity to recognize a number of ligands, such
as fibrinogen, complement fragment iC3b and ICAM-1 to mediate leukocyte adhesion
and migration, and are thus implicated in inflammation.61 Studies have shown the
independent role of CD11b and CD18. Cells expressing only the ⍺M subunit (ITGAM)
can recognize ligands, normally recognized by the integrin ⍺Mβ2, independently of the β2
subunit, and subsequently mediate firm cell adhesion and spreading in response to these
ligands.61
Studies measuring CD11b expression in maternal sera or macrophages of the placenta
also have conflicting reports.63-65 In maternal sera from PE patients, one study reports an
increase while another reports no change.63,64 In placental macrophages, two studies
isolated Hofbauer cells and only one reported ITGAM expression.65,66 Meanwhile, in
trophoblast cell culture, a study investigating the role of chemokines in promoting
trophoblast cell migration via regulation of adhesion molecules and extracellular matrix
components, ITGAM showed a two-fold increase in trophoblast cells upon treatment with
chemokines.67 A more recent study utilized a microarray approach for transcriptional
profiling of the syncytiotrophoblast, invasive, and endovascular cytotrophoblast layers in
placenta from women with severe PE, using preterm births as controls.68 RNA profiles
show increased expression of ITGAM in the endovascular cytotrophoblast samples
compared to the syncytiotrophoblast and invasive cytotrophoblast samples from both PE
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and preterm placenta.68 However, there were no differences in ITGAM expression in any
of the samples between PE and preterm placenta.68 In pregnant mice, the expression of
ITGAM has been strongly localized to the spongiotrophoblast layer and was shown to
increase across gestation.69 In this study staining for ITGAM in whole placental tissues
localized ITGAM to intermediate CT cells in the BPD (Figure 3.5 e,f).
3.4.3.3 APLN
Apelin is the ligand for the G-protein-coupled receptor angiotensin II receptor-like 1, also
known as APJ.59,60 The role of APLN is well investigated in the cardiovascular system
and is known to play a role in angiogenesis.70-72 The exact role of APLN in the human
placenta is not yet fully elucidated, however both APLN and APJ are expressed in the
human placenta, with evidence of temporal expression, decreasing as the placenta
matures.73 More specifically, immunohistochemical staining shows expression of APLN
and APJ in the CT, SCT and vascular endothelial cells of the placenta.73-75 In this study
staining in preterm controls and PE +IUGR placenta localizes APLN to the same cell
types as well as to intermediate cytotrophoblasts in the BPD (Figure 3.6 a-d). As for the
expression of APLN in placenta from PE and IUGR pregnancies, while there are some
studies that report no differences, many report a downregulation of APLN and APJ
mRNA and protein in severe PE patients.73-77 A severe down regulation of APLN is noted
particularly in patients with PE and IUGR.73,77 In our previous report of gene expression
profiling in patients with early onset complications, we identified APLN to be only
downregulated in patients with PE + IUGR, but not in PE only or the IUGR only groups
compared to gestational age-matched controls. Apelin was also recently investigated as a
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potential therapeutic agent in a rat model of PE, and was found to inhibit oxidative stress,
one of the common hallmarks of PE.78
3.4.3.4 FGF13
Fibroblast growth factor-13 (FGF13) belongs to the FGF homologous factor (FHF)
subfamily.79 Unlike most fibroblast growth factors, FGF13 acts intracellularly in a
FGFR-independent manner.79 This intracellular protein is found to be expressed in the
nervous system, including the brain, as well as muscle cells, and more recently in cancer
cells.80-82 In the nervous system FGF13 is an important regulator of neuronal
development, as it plays a role in neural differentiation and regulates the migration and
polarization of neurons.80,83 In cancer cells, FGF13 is upregulated, and its upregulation is
thought to be beneficial for cancer cells.82 In human cancer cell lines, knock-down of
FGF13 induced apoptosis, whereas overexpression restricted accumulation of reactive
oxygen species and promoted cell survival.82 Although not well investigated in the
human placenta, FGF13 is expressed in placenta trophoblasts (results from the Human
Protein Atlas Database, http://www.proteinatlas.org/ENSG00000129682-FGF13/tissue).
A more recent 2018 report by Yue et al.,84 identified FGF13 to be expressed in
trophoblast cells of the placenta using immunofluorescence and cytokeratin-7 as a
positive trophoblast marker.84 In the same report, FGF13 mRNA and protein are reported
to be downregulated in patients with severe PE and is proposed to play a role in
trophoblast permeability.84 We previously reported the down-regulation of FGF13 and
using qRT-PCR in this report, we confirmed the down-regulation of FGF13 in patients
with early-onset PE only, IUGR only, and PE + IUGR. Immunohistochemical staining
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localized FGF13 to SCT cells in the CV and was also localized to intermediate CT cells
in the BPD (Figure 3.6 e-h). To our knowledge, this study is the second to report FGF13
down-regulation in early-onset PE patients, and the first to report it in early-onset IUGR
only, and PE + IUGR patients.

3.5

Conclusion

In conclusion, this study contributes to our knowledge of miRNAs and their potential
impact on placental growth/development and function. Here, we report the upregulation
of miR-210-5p and miR-193b-5p in patients with early-onset complications. Luciferase
assay results and mRNA expression levels of candidate targets in treated HTR-8/SVneo
cells supports potential regulation of CSF1 and ITGAM by miR-210-5p, and APLN and
FGF13 by miR-193b-5p. These gene targets were localized to intermediate CT cells in
the BPD and potentially play an important role in placental function. Additionally, the
two miRNAs impact the ability of HTR-8/SVneo cells to proliferate and migrate,
providing further evidence for the role of miRNAs in cellular functions. To further
confirm findings, future experiments can focus on: (i) creating point mutations in the
3´UTR regions of gene targets to confirm sequence specificity, (ii) conducting the same
experiments in another trophoblast cell line more representative of 3rd trimester placenta,
such as BeWo, (iii) use siRNAs to knock down or decrease gene target expression in cell
culture and measure functions such as proliferation, migration, and adhesion. Further
studies investigating and validating miRNAs and gene-target interactions will be useful
in expanding our knowledge of the role of microRNAs in disease, and particularly their
impact on trophoblast cells necessary for placental health and function.
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Chapter 4

4

General Discussion

4.1 Summary and Perspective
MiRNAs are short, single-stranded, endogenous RNA molecules that are abundantly
expressed in most human tissues. MiRNAs regulate gene expression by targeting mRNA
transcripts in the cytoplasm via sequence complementarity. MiRNA targeting
mechanisms may then result in either (i) degradation of the mRNA transcript, or (ii)
blocking of translational machinery. Some miRNAs are tissue specific, such as miRNA
clusters C14MC and C19MC expressed on chromosomes 14 and 19 respectively, in the
human placenta.1 Expression levels of placenta-specific miRNAs are also found to be
different in first versus third trimester placenta.2 Collectively, these discoveries sparked
interest in the role of miRNAs in placental growth and function, and particularly their
role in disease.
This study utilized NGS technology to measure global expression levels of miRNAs in
placental samples from three distinct patient groups diagnosed with early-onset
pregnancy complications (PE only, IUGR only, or PE + IUGR) in comparison to
placentae from gestational-age matched controls. This not only allowed us to identify
miRNAs that are differentially expressed in each disease group, but also to compare the
diseased groups to identify miRNAs that are common and unique to each disease. To
investigate the potential impact of alterations in miRNA expression on gene expression in
the placenta during disease, we again used NGS technology to measure global gene
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expression levels in the same patient samples. This analysis also allowed us to identify
genes differentially expressed in each disease group as well as genes that are common
between the pregnancy complications. Findings from the miRNA and gene expression
analyses are reported in Chapter 2.
After completion of the differential expression analysis for miRNAs and genes in the
same patient samples, the expression data sets were integrated using inverse correlation
analysis. We sought to identify any differentially expressed miRNAs that were
significantly inversely correlated with any differentially expressed genes in each patient
group, i.e. upregulated miRNA and downregulated gene or vice versa. This analysis was
used to guide our initial search for potential gene targets impacted by dysregulated
miRNAs. The list of potential gene targets of interest was then further refined to include
genes that were predicted by software prediction tools for the miRNA of interest. Two
miRNAs became of interest following inverse correlation analysis and target prediction,
miR-210 and miR-193b. These two miRNAs were upregulated in all three patient groups
(PE only, IUGR only, and PE + IUGR) compared to controls, and the majority of
predicted genes are targets for either miR-210-5p, miR-193b-5p or in some cases both.
Predicted gene targets were identified in all three patient groups, however majority of the
genes were in the PE + IUGR patient group.
Chapters 3 focused on investigating the identified candidate gene targets from chapter 2
for miR-210-5p and miR-193b-5p. For each miRNA the studies in chapters 3 aimed to
confirm miRNA: mRNA interactions using luciferase assays and to measure impact of
miRNA dysregulation on important cell functions such as migration.
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4.1.1

MicroRNA expression in early pregnancy complications

MicroRNA differential expression analysis identified six upregulated miRNAs that are
common to all three patient groups with early-onset pregnancy complications compared
to gestational-age matched controls. All six miRNAs have previously been identified to
be upregulated in placenta from PE pregnancies.3-11 However, none of the six miRNAs
have previously been identified in placenta from IUGR pregnancies. Findings from our
study overlapped significantly with findings from two other studies, Ishibashi et al. and
Zhou et al., that also used NGS technology to measure miRNA expression.3,7 However, it
is important to note that patients used in these two studies are likely diagnosed with lateonset PE.3,7 Segregation of patient groups into early- and late- onset in scientific studies
is beneficial to expand our understanding of molecular mechanisms that are unique based
on onset of clinical symptoms, and mechanisms that are common regardless of the
gestational age of the onset of symptoms. The most commonly identified dysregulated
miRNAs were miR-210 and miR-193b-3p.3-11 Since miR-210 is one of the first miRNAs
to be associated with PE9, subsequent studies focus on the impact of miR-210 on
placental growth and function.12-15 Indeed, many studies now solely investigate the
impact of miRNAs by identifying candidate gene targets and measuring important cell
functions, particularly in trophoblast cells.
In our study, a subset of miRNAs remained unique to either PE or IUGR placenta, with
the majority of miRNAs in the IUGR only group. Three miRNAs were unique to PE
placenta (+/- IUGR) and two more were unique to patients with PE only. The majority of
miRNAs differentially expressed in the IUGR only group remained unique to this patient

129

group (31/37). Studies measuring miRNA expression in placenta from IUGR pregnancies
are scarce and overlap between our findings in this patient group compared to other
studies is limited. This can be attributed to (i) heterogeneity of disease etiology, (ii)
distinction between pathological vs. non-pathological forms of the condition (IUGR vs.
SGA), and (iii) differences in patient population (Late- and early-onset, +/- PE).
However, there is literature evidence for dysregulation of miRNAs in the C19MC in
IUGR pregnancies.16,17 Our study identified 4 miRNAs that belong to the C19MC cluster
and 6 that belong to the C14MC cluster that are dysregulated in IUGR only placenta,
emphasizing the potential role of these placenta-specific miRNA clusters in pregnancy
complications.1
Although pregnancy complications such as PE and IUGR are treated distinctly and have
different clinical manifestations, miRNA expression results provide evidence for some
common molecular mechanisms in the placenta potentially involved in disease
pathogenesis. Although impact on gene expression may vary between disease groups, the
underlying mechanisms impacting changes in gene expression maybe similar and directly
involved in disease process of PE and IUGR.

4.1.2

Gene expression in early pregnancy complications

Global gene expression analysis in the three patient cohorts revealed results similar to
results from the miRNA expression analysis, in that a subset of genes is common to all
three patient groups, whereas other genes exhibited specificity to the disease (PE or
IUGR) or the specific patient group. A total of 22 genes are differentially expressed in all
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three patient groups, many of which have been identified in studies measuring global
gene expression in placenta from PE pregnancies (CST6, FSTL3, INHA, SLCO2A1,
TGFb1).18-22 To our knowledge only 3 of the 22 genes common to all three patients
groups have been reported in multiple disease groups in the literature. One gene is
FSTL3, which has been identified to be upregulated in placenta from IUGR
pregnancies.25 As well as, F13A1 and FAM101B, which have been reported to be
downregulated in a study measuring global gene expression in patients with late-onset PE
co-occurring with IUGR, providing evidence for overlapping patterns of gene expression
between PE and IUGR.19 This was also shown more recently in a study conducted by
Gibbs et al., where unsupervised cluster analysis of placental transcriptional and
histological data from normotensive and hypertensive patients with IUGR revealed
overlap between the patient groups based on both transcriptional and histological data.26
Differential gene expression analysis also revealed 141 genes unique to patients with PE
(+/- IUGR) providing evidence for the large changes in the transcriptome observed in
placenta from PE pregnancies. A large subset of these genes overlap with findings in the
literature, with both late-18-21 and early-onset22 PE studies, but more so in early-onset
studies. This emphasizes the importance of segregating patient populations based on
onset of symptoms allowing us to compare findings to better understand the underlying
molecular manifestations of each form of disease. Studies measuring expression in earlyand late-onset PE including this study agree on a core group of genes that are consistently
identified to be dysregulated in PE placenta, these genes include but are not limited to:
ENG, FTL1, FSTL3, INHA, INHBA, LEP, HTRA4, SASH1.18-22 Global gene expression
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studies in placenta from IUGR pregnancies are scarce and overlap with existing studies is
limited. This is likely due different definitions of patient populations in these studies that
may include both pathological and non-pathological forms of the disease.27,28 A few
genes that did overlap between our patient groups with IUGR and reports in the literature
include: BMP1 in the IUGR only group, NFASC, FAM20A and RBP1 in the PE + IUGR
group.23,24 On the other hand, in comparing these studies investigating placental gene
expression in IUGR pregnancies it became apparent that many genes within the same
family are commonly dysregulated but not the same exact gene, examples include:
ADAM, GFOD, GLRX, NUDT, PLCB, RNF, and SCARB.23,24
Findings from this global gene expression study provide further evidence that although
PE and IUGR are distinct pregnancy complications, there are common perturbations in
placental transcription potentially contributing to both conditions. Meanwhile genes
unique to each pregnancy complication provide evidence that there are perhaps maternal
and fetal contributions that are observed in PE and IUGR respectively.

4.1.3

MicroRNAs and genes in placental growth/development and
function

Investigation of the role of miRNAs in pregnancy complications is an important step to
understand the impact of miRNAs on placental health and function. To accomplish this,
studies focus on identifying (i) important candidate gene targets for miRNAs and (ii)
measure changes in biological and cellular functions. In the last 5 years, there has been a
surge in studies investigating the functional role of miRNAs in pregnancy complications
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and in other diseases as well, particularly cancer. Table 4.1 shows some of the miRNAs
that we report to be differentially expressed in our patient groups and reports in the
literature that involve these miRNAs in biological functions important for placental
growth and function. Migration, invasion, and proliferation are the most common
biological functions associated with these miRNAs. These biological functions are most
important in the process of spiral artery remodeling, thought to be dysregulated in
pregnancy complications such as PE and IUGR. Intermediate CT cells must differentiate
into EVT cells that have migration and invasion capabilities to properly remodel spiral
arteries. Studies listed in table 4.1 provide evidence for how miRNAs can be involved in
regulating these important biological functions. Studies on miR-210 provide the earliest
evidence of the involvement of miRNAs in these biological functions particularly
migration and invasion.12-15 Multiple validated miR-210 targets are known to be involved
in regulating EVT cell invasion, they include EFNA3, HOXA9, and THSD7A.12,14 While
miR-210 is upregulated in PE pregnancies, these gene targets are found to be
downregulated. Another example is miR-515-5p, a member of C19MC that is
upregulated in IUGR placenta and has been validated to target CYP19A1, FZD5, and
GCM1 three genes important for human trophoblast differentiation.44 MiRNAs identified
in this study and other studies are synthesized in the chorionic villi and their potential
role in the regulation of expression of genes involved in the proliferation and invasion of
EVTs and remodeling of spiral arteries occurs in the decidual plate of the placenta and
the endometrium of maternal uterus. Most miRNAs are synthesized in trophoblast cells
and can exert their biological functions in the same cell or nearby cells. It is possible that
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the identified miRNAs are expressed in EVTs or nearby cells, however, this was not
investigated in this study.
Table 4.1 includes studies reporting on these miRNAs in the context of pregnancy
(reference indicated in bold) and in the context of cancer. There are many parallels
between placental and tumor development, including mechanisms for regulating
proliferation, invasion and immune tolerance.48-50 Table 4.1 does not represent a
comprehensive list of miRNAs, there are more miRNAs identified in the literature
showing similar implications in migration, invasion, and proliferation. In addition to
identified miRNAs providing evidence for trophoblast cell dysfunction in these
pregnancy complications, a subset of genes that this study reported to be differentially
expressed in all three patient groups are also directly implicated in the same biological
cell functions. Table 4.2 lists 7 genes that are a part of the 22 genes common in patients
with PE and/or IUGR that have been shown in the literature to be involved in biological
functions such as: migration, invasion, and differentiation. Studies referenced in table 4.2
all directly address the role of these genes in the context of trophoblast cells and direct
impact on placental growth and function. In conclusion, both miRNAs and genes
commonly dysregulated in all three patient groups provide evidence for trophoblast
dysfunction present in placenta from PE and IUGR pregnancies and could be a direct
contributor to the co-occurrence of these complications in a subset of patients (PE +
IUGR).
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Table 4.1 MicroRNAs identified in patient groups also previously described in the
literature to impact important biological functions

References in bold indicate studies measuring impact on biological function within the
context of the placenta and/or pregnancy complications.
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Table 4.2 Genes identified in all patient groups with pregnancy complications are
important for trophoblast biological functions

4.2

Limitations

This study contains a number of inherent limitations. Differential expression analysis in
this study is conducted in comparison to gestational age-matched controls. Although it is
beneficial to compare placental samples of similar gestational age because of the prime
consideration of comparing placental tissues that are of similar developmental stages,
controls in this study are from preterm births that may not be considered normal nor
healthy since evidence shows that preterm births are a result of perturbations during
gestation some of which can be attributed to the placenta. In the future, inclusion of both
preterm and term controls may be beneficial for understanding how selection of control
samples impacts results. Inclusion of labored and non-labored controls is also important
to further investigate impact of labor on placental miRNA and gene expression. Due to
sample scarcity and time limitations, a secondary validation cohort was not included in

136

this study. Including a discovery and validation cohorts is beneficial to ensure that
findings are replicable, concrete, and independent of any experimental biases.
Analysis in this study also assumes that cellular compositions across tissue samples is
equal however that is likely untrue, even though we conducted multi-site placental
sampling focused solely on the fetal side of the placenta. The placenta contains a mosaic
of cell types that can exist at varying ratios due to inherent variability between patient
samples or variability in tissue sampling. To resolve this limitation, fast and effective
methods for isolation of different cell types within the placenta are necessary. In addition
to the importance of establishing transcriptional profiles in order to identify contributions
of each cell type to the placental transcriptional landscape. Finally, as with all
investigations of delivered placental samples, it is impossible to delineate whether
observed molecular differences are part of the cause or the consequence of disease.

4.3

Future Studies

There are many future studies that can stem from this work. Since miRNAs are known to
enter maternal circulation during pregnancy, one important future study would be to
measure miRNA levels in maternal plasma of patients diagnosed with PE and/or IUGR to
assess miRNA diagnostic potential, particularly miRNAs identified in all three patient
groups. More recent research demonstrates the potential use of placental exosomes as
biomarkers with standardization of isolation methods and identification of placenta
specific markers for exosomes.66,67 Some miRNAs belonging to the C19MC have been
detected in exosomes from primary trophoblast cells.66

Another marker is PLAP
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(Placental Alkaline Phosphatase) present on exosomes only in the peripheral circulation
of pregnant women.67 PLAP is mainly produced from SCT cells but has also been
identified in other trophoblast cell types in the placenta.68,69 For a future study, analysis of
maternal plasma samples for exosomes or cell-free RNA can be completed
retrospectively by measuring miRNA levels in plasma samples obtained early in
pregnancy as a part of routine clinical care to more accurately assess predictive value
across gestation.
Findings from global expression studies in the placenta can also be coupled with other
clinical and histopathological information to better understand trophoblast dysfunction
contributing to poor placental growth and function in PE and IUGR pregnancies. Finally,
identification and validation of miRNA gene targets is an important future study to
continue to expand our understanding of miRNAs and their role as epigenetic regulators
in the placenta. Integration of multi-level molecular information combined with in vitro
techniques is a useful approach. However, investigating individual miRNAs using
targeted approaches combined with target prediction software and in vitro techniques is
equally effective. In vitro techniques can also include assessing the impact of hypoxia on
miRNA and gene target expression, since the intrauterine environment in PE and IUGR
pregnancies is thought to be hypoxic.

4.4

Conclusion and Significance

In conclusion this study identified miRNAs and genes differentially expressed in three
patient groups with early-onset pregnancy complications (PE only, IUGR only, and PE +

138

IUGR), and further investigated the potential impact of miRNAs on gene target
expression and biological functions important for trophoblast cells of the placenta (figure
4.1). This study expanded our knowledge of molecular changes in the placenta in each
patient group by identifying miRNAs and genes that are common and unique to each
pregnancy complication. Additionally, this study provided further evidence for the role of
miRNAs and their impact on placental growth/development and function.

Figure 4.1 MicroRNAs impact gene expression and biological functions
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